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ABSTRACT OF DISSERTATION 
 
 
A COMPROMISED LIVER ALTERS PCB TOXICITY AND NUTRIENT 
METABOLISM 
 
Environmental contamination is a public health concern. In particular 
persistent organic pollutants like Polychlorinated Biphenyls (PCBs) have been 
associated with multiple chronic inflammatory diseases, including non-alcoholic 
fatty liver disease (NAFLD). NAFLD prevalence has steadily increased and is 
expected to continue to rise with an estimated 25% of the world’s population and 
80-100 million people affected in the United States alone. Importantly, the liver is 
the primary site for endobiotic and xenobiotic metabolism; hence its proper 
function is critical for the body’s response to innate and extrinsic molecules. One 
way to combat the deleterious effects of PCB toxicity and fatty liver disease is by 
increasing consumption of beverages and foods that contain beneficial bioactive 
nutrients, like dietary polyphenols. However, the biological properties of these 
dietary compounds are subject to their bioavailability which is directly dependent 
on the activity of the liver. 
 
The first aim of this dissertation was to test the hypothesis that in the 
presence of a compromised liver, PCB-126 toxicity is altered. Indeed, hepatic 
and systemic PCB-126 toxicity was exacerbated in this severe liver injury mouse 
model with an observed increase in hepatic inflammation, systemic inflammation, 
and early markers of endothelial cell dysfunction. Interestingly, we also observed 
an increase in the novel gut-liver axis derived cardiovascular disease (CVD) 
marker trimethylamine-N-oxide (TMAO). Taken altogether, aim 1 proved that a 
compromised liver can alter PCB toxicity, with implications of the gut microbiota 
in disease pathology.  
 
In aim 2 we investigated whether GTE can protect against MCD-induced 
hepatic toxicity and development of NAFLD. Results indicated that MCD mice 
exhibited severe liver injury and gut dysbiosis and unexpectedly, GTE had no 
protective effects. Interestingly MCD mice displayed differential epigallocatechin-
3-gallate (EGCG) metabolism at the hepatic and gut microbiota level, which may 
alter polyphenol bioavailability and therapeutic potential. Overall, the results 
provide insight into how a dysfunctional liver and gut dysbiosis can alter 
polyphenol metabolism, possibly reducing its therapeutic efficiency.  
 
In aim 3 we sought to determine potential protective effects of a prebiotic 
in this mouse model. MCD-fed mice were exposed to PCB-126 with or without 
inulin supplementation. Although findings from this study are preliminary, our 
evidence indicates that inulin restores body weight and body composition in this 
MCD+PCB mouse model and alters the expression of Cyp1a1 in PCB exposed 
mice, suggesting that inulin’s protective effects may be a result of its ability to 
interact with the AhR pathway. However further analysis will need to be done to 
examine the effects of inulin on hepatic, systemic, and gut microbiota endpoints.  
 
Overall the data contained in this dissertation suggests that in the 
presence of a compromised liver both pollutant toxicity and nutrient metabolism 
are altered, with implications of the gut-microbiota in disease risk. These findings 
suggest that individuals with end stage liver injury may be more susceptible to 
pollutant-induced toxicity and nutritional intervention may be unsuccessful at 
mitigating disease risk. 
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Chapter 1:  Introduction 
 
Chronic inflammatory diseases 
 
 Chronic inflammatory diseases are a national health burden and currently 
affect millions of people globally. Although the human body naturally uses 
inflammatory mechanisms for tissue and wound healing, chronic inflammation 
can have detrimental effects. Inflammatory diseases can take form in different 
organs of the body including in the adipose tissue causing obesity, in the heart 
contributing to coronary artery diseases like atherosclerosis, in the gut resulting 
in illnesses such as inflammatory bowel disease and the more recently studied 
gut dysbiosis, or even in the liver causing fatty liver diseases and hepatic cancers 
[1-5]. One important notion to consider is that each of these chronic inflammatory 
diseases can be a risk factor for another, allowing for increased risk of 
developing multiple diseases in many individuals. One such disease that has 
been implicated as a risk factor for many others and that is becoming a global 
public health concern is non-alcoholic fatty liver disease (NAFLD).  
 
Non-alcoholic fatty liver disease (NAFLD) 
 NAFLD is a major public health problem and the most common chronic 
liver disease as its prevalence has steadily increased, representing over 75% of 
the chronic liver disease cases, and is expected to continue to rise [6]. An 
estimated 25% of the world’s population and 80-100 million people affected in the 
United States alone are suffering from the disease with the current medical and 
societal costs estimated at $292 billion a year [7-9]. NAFLD is the hepatic 
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manifestation of metabolic syndrome and is characterized as a spectrum of 
progressive liver diseases that is produced in the absence of severe alcohol 
consumption. The incidence of this disease has increased with the growing 
sedentary population, suggesting that lifestyle choices including poor diet and 
lack of exercise are major contributors to the development of NAFLD. In fact, a 
significant risk factor for NAFLD progression and development is being obese 
[10]. Risk factors in addition to obesity that also contribute to the development of 
NAFLD  include type 2 diabetes, insulin resistance, and dyslipidemia, all of which 
are hallmarks of metabolic syndrome [11]. NAFLD is histologically defined as the 
ectopic accumulation of lipid in the hepatocytes and ranges in severity with the 
earliest forms being reversible. It begins with steatosis which is simple fat 
accumulation in the liver of greater than 5% in the hepatocytes (histologically) 
which can then progress to steatohepatitis which is the presence of fat and 
inflammation with or without fibrosis [12, 13]. Although steatosis and 
steatohepatitis are reversible forms of the disease, once the liver develops late 
stage scarring it is considered cirrhosis which is irreversible.  
 Although the causative mechanisms of NAFLD remains uncertain, many 
theories have been proposed to explain its development and progression. The 
“two-hit” or more recently “multiple-hit” hypothesis is the most widely accepted in 
the field of hepatology. This theory suggests that there is a first “hit” to the liver 
that initiates ectopic fat accumulation in the hepatocytes causing an imbalance in 
synthesis, influx, oxidation, and export of hepatic lipids [14, 15]. This increase in 
lipids can be a consequence of many sources including being diet-induced as a 
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result of the increased consumption of high caloric and fat rich foods. At this 
stage the liver is vulnerable to a second insult deemed the second “hit” which can 
be an effect produced by cytokines, oxidative stress, or gut-derived components 
[15].  
 
The effects of a dysfunctional liver on drug and nutrient metabolism  
 It is pertinent for individuals to have a properly functioning liver since it is 
the chief organ responsible for the metabolism of both endogenous and 
exogenous substances. For this reason, multiple studies have investigated the 
ability of non-alcoholic steatohepatitis (NASH) to alter drug pharmacokinetics and 
ultimately influence the toxicity of pharmaceutical drugs. For example, Clarke et 
al. demonstrated that mice fed the NASH producing MCD diet exhibited 
alterations in metformin metabolism, causing increased risk for drug toxicity [16]. 
Another study in MCD-diet fed mice showed changes in the kidney, particularly 
the glomerular filtration and tubular secretion of the drug adefovir, causing 
alterations in the pharmacokinetics [17]. This is an important concept since not 
only can a dysfunctional liver alter drug metabolism, but similar effects can be 
seen with other endogenous components like pollutants and possibly beneficial 
nutrients [18, 19].  
 
The Gut-Liver Axis 
 
As stated above, the liver is the major site for endogenous and exogenous 
metabolism, hence a healthy and properly functioning liver is crucial to overall 
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host health. With regard to the liver, a critical feature to take into account is that 
the liver has a rich blood supply and is able to interact with multiple organs in the 
body. This cross-talk is crucial to understanding the development and 
progression of multiple disease states and studies focused on this has become a 
prevalent area of research across all fields over recent years. For example, 
NAFLD has been implicated in the perturbation of the gut microbiota in both 
rodent models and in human studies as seen by alterations at the phyla and 
genus level of microbes [20, 21]. Recent literature has indicated that the gut 
microbiota participates in a co-partnership with the liver, dubbed the gut-liver 
axis, and has an impact on the pathology of multiple chronic inflammatory 
diseases including NAFLD [22]. For example J. Henao-Mejia, et al. showed that 
mice fed a MCD diet developed a NASH phenotype which was associated with 
changes in the composition of the gut [23]. On the other hand, gut dysbiosis can 
also contribute to NAFLD by influencing the regulation of energy homeostasis, 
modulation of bile acid synthesis, and formation of pro-inflammatory toxins that 
target distant organs like the liver [22]. 
 
The Gut Microbiota 
The gut microbiota is an organ with a diverse microbe population weighing 
in at about 2 kg that resides in the gastrointestinal tract of the host. It plays a 
major role in overall host health by aiding in digestion, contributing to metabolism 
of dietary and host-derived molecules, combating other microorganism, and 
acting as a first line of defense to the external environment [21]. Multiple 
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elements shape the identity and composition of the gut microbiota. Some 
examples includes the mode of birth of a newborn fetus, the age of a person, 
exposure to environmental contaminants, the use of antibiotics, and lifestyle 
choices such as diet and exercise [24-27]. Additionally, since the primary route of 
exposure to many pollutants is via oral intake of food and water, the gut 
microbiota’s location makes it not only at great risk to be affected by these 
pollutants, but also makes it susceptible to dietary manipulation. In fact, Petriello 
and Hoffman et al. showed that exposure to the environmental pollutant 
polychlorinated biphenyl 126 (PCB-126) can increase intestinal inflammation and 
disrupt gut microbiota homeostasis in an atherogenic mouse model [28]. Still, 
ongoing research is making strides to try and identify techniques to prevent and 
reduce disease risk utilizing nutritional therapeutics targeting the gut microbiota 
[29, 30]. The gut microbiota also plays a huge role in host metabolism and 
energy regulation, allowing it to influence overall host health and disease 
outcomes in a major way. A healthy gut contains a diverse population of 
microbes and an imbalance of the intestinal bacteria, known as gut dysbiosis, is 
associated with disease development including metabolic disorders, 
atherosclerosis, and NAFLD [31].  
 
Environmental pollutants and disease 
 
The effects of exposure to environmental contamination impact almost 
every living population throughout the world. This is because environmental 
pollutants have been linked to a variety of disease outcomes and the 
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pathogenesis of numerous inflammatory diseases. There are multiple routes of 
exposure that can contribute to the increased body burden of environmental 
contaminates, with the most significant exposure sources being dermal, 
inhalation, and oral [32, 33]. Although we can encounter pollutants through all of 
the before mentioned routes, one of the primary ways that persons come into 
contact with pollutants is via the oral route, usually by accidental ingestion 
through contaminated food and water sources. At the cellular level pollutants 
exert their actions by various signaling pathways, depending on the 
concentration present in the cell and the cell type it effects.  
 
NAFLD and environmental pollutants 
  The progression of fatty liver disease and related metabolic dysfunctions 
have historically been linked to an imbalance in energy intake and expenditure. 
However, recent epidemiological studies have shown an association of exposure 
to environmental pollutants, such as PCBs with the induction or exacerbation of 
several chronic inflammatory and metabolic diseases including obesity, 
cardiovascular disease, diabetes, and liver disease [34-38]. Toxicant-associated 
fatty liver disease (TAFLD) and the more severe form toxicant-associated 
steatohepatitis (TASH) has become an important field of study, relating 
environmental and occupational exposures to pollutants like PCBs and vinyl 
chloride respectively with the development of fatty liver disease [35, 39, 40].  
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NAFLD and Polychlorinated Biphenyls (PCBs) 
 More specifically, PCBs are part of a bigger class of pollutants often 
referred to as persistent organic pollutants or POPs. These are typically 
environmental contaminants that are resistant to degradation and bind to a 
variety of cellular receptors initiating signaling cascades thereby creating 
conditions that is advantageous to disease progression. PCBs are man-made 
aromatic chemicals that were widely used in industrial applications until their 
outlaw in the United States in the 1970s and worldwide in 2001 [41]. There are 
over 200 PCB congeners that are categorized by their structure and the degree 
of chlorination, with the replacement of hydrogen with chlorine atoms in the ortho 
positions of the benzene rings creating an altered configuration. This substitution 
of chlorine atoms in different positions on the aromatic rings enables coplanar 
and non-coplanar configurations and specific interactions with regulators of 
detoxification, the xenobiotic cellular receptors. Coplanar, dioxin-like PCBs 
including PCB-126 are agonist of a transcription factor called the aryl 
hydrocarbon receptor (AhR) while non-coplanar, phenobarbital-like PCBs such 
as PCB 153 act on the constitutive androstane receptor (CAR)/pregnane X 
receptor (PXR) [42-44]. In addition, PCBs have high thermal stability and their 
hydrophobicity and resistance to metabolic degradation which allows them to 
biomagnify in the food chain, eventually leading to their bioaccumulation in 
human adipose tissue. Today, most human exposures to PCBs are through 
contaminated food sources, allowing for PCBs to cause disruption to several 
organ systems [45]. 
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 In the cytoplasm of the cell, PCB-126 binds to the AhR, causing the 
disassociation of chaperone proteins from the receptor and subsequent 
translocation to the nucleus. AhR then heterodimerizes with the co-factor aryl 
hydrocarbon receptor nuclear translocator (ARNT) and binds to xenobiotic 
response elements (XRE) in the promoter region of AhR target genes, including 
detoxifying enzymes such as cytochrome P450 1A1 (Cyp1A1). The chronic 
exposure to PCBs can lead to chronic activation of the AhR and increased 
expression of its downstream target genes, causing decoupling and the release 
of reactive oxygen species (ROS). This chronic inflammatory and oxidative 
stressful state is what is believed to be the mechanism by which PCBs elicits the 
development, progression, or exacerbation of chronic inflammatory diseases like 
NAFLD. For instance with regards to liver diseases like NAFLD and 
hepatocellular carcinoma, pollutants like 2,3,7,8- tetrachlorodibenzo-p-dioxin 
(TCDD) and PCB-126 can increase risk and disease severity by activating AhR, 
subsequently increasing hepatic and systemic inflammation [43, 44]. 
 
Rodent models of NAFLD  
 
 There are multiple rodent models that exist to investigate NAFLD and 
many have been used to mimic human liver disease [46]. However, choosing the 
right model for study is pertinent, as they all have both benefits and limitations. In 
particular, the highly reproducible MCD-diet mouse model has been extensively 
used in research to mimic human NASH. This diet typically contains a significant 
carbohydrate source but is deficient in both methionine and choline. Choline is a 
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major component of very-low-density lipoprotein (VLDL) and the lack of this 
nutrient leads to impaired hepatic production and secretion of lipoproteins, 
subsequently resulting in ectopic fat accumulation in the liver [47, 48]. 
Additionally, a deficiency in choline alters the mitochondrial function, producing 
fatty acid oxidation disturbances [49]. Methionine plays a different role in NASH 
development within this diet. Methionine is important for not only protein 
synthesis, but also the synthesis of anti-oxidant molecules such as S-
adenosylmethionine (SAM) and glutathione. The absence of this essential amino 
acid causes hepatic methyl imbalance and oxidative stress, contributing to the 
development of NAFLD [50-52]. All of this is important, with choline deficiency 
leading to the human NAFLD phenotype while methionine deficiency promotes 
oxidative stress and possibly drives an inflammatory response by alterations in 
cytokine production [53, 54].   
 Moreover, the use of animal models is an important tool for investigating 
the molecular mechanisms that contributes to the development of diseases as a 
result of pollutant exposures. A benefit of using the MCD-diet model to study 
NASH is that when mice are fed this diet, they do not become obese and instead 
exhibit weight loss, producing a lean phenotype [46]. Although it is true that 
human NASH is closely associated with obesity using a lean mouse model is 
crucial when studying TASH, especially when examining the effects of lipophilic 
pollutants. Other popular NAFLD rodent models like high-fat diet (HFD) feeding is 
not the most advantageous to study these classes of pollutants because it has 
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been shown that obese mice are protected against the effects of lipophilic 
pollutants as an increase adipose stores limits pollutant bioavailability [55].  
 
Nutritional Intervention 
 
 Even with increased effort and programs to decrease the public burden of 
environmental exposures and significant advancements in modern day medicine, 
there still remains a deficiency in the treatment of inflammatory diseases. With 
respect to NAFLD, the current clinical treatment for the disease is to decrease 
weight by 10% through decreased caloric consumption and increased exercise. 
Unfortunately, this method has proven difficult to maintain in practice with limited 
long-term success [56, 57]. Thus, a recent clinical guideline that has been 
suggested by clinicians and the like is increasing consumption of more nutrient 
rich foods to decrease or ameliorate countless inflammatory and pollutant-related 
diseases including diabetes, obesity, fatty liver disease, and gastrointestinal tract 
illnesses. One reason this therapy is so promising is that most of these pollutant-
induced non-communicable diseases exert their harmful health results via 
signaling mechanisms associated with oxidative stress, inflammation, and 
carbohydrate and lipid metabolic pathways, which are the same mechanisms that 
many beneficial nutrients act on. Similarly, the ailments from exposure to 
environmental toxins like PCB-126 also results from these pollutants working 
through these same molecular pathways, permitting beneficial nutrition to be a 
promising means to contest undesirable health outcomes associated with 
environmental pollutant and diet-induced diseases.  
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Green Tea and related beneficial metabolites 
 One dietary intervention that has been associated with a decrease in 
NAFLD development and progression is increased consumption of tea. Tea is 
the 2nd most consumed beverage in the world just behind water and has been 
used for centuries as a means to combat disease. The manufacturing process of 
tea allows for six different classification groups: green, black, yellow, white, dark, 
and oolong. This difference in processing contributes to multiple properties and 
characteristics distinct to the class of tea such as color, taste, and aroma. In 
particular, green tea accounts for 20% of the world’s tea consumption [58]. 
Moreover, green tea and its major bioactive polyphenolic catechin 
epigallocatechin-3-gallate (EGCG) have been well studied as a therapeutic for 
NAFLD using in vitro and in vivo models in recent years [59-61]. EGCG along 
with epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epicatechin (EC) 
are the most abundant catechins found in green tea with EGCG accounting for 
50-75% of the total catechin abundance [58, 62]. Although the exact biological 
effects of EGCG and other green tea polyphenols are still under investigation, it 
has been shown that these molecules can decrease expression of hepatic 
transcription factors involved in downstream inflammatory responses and 
increase expression of transcription factors involved in the activation of 
antioxidant response, resulting in anti-inflammatory and anti-oxidant properties 
respectively in rodent models of fatty liver disease [63, 64]. However, the 
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biological properties of dietary polyphenols are subject to their bioavailability 
which is directly dependent on the activity of the liver.  
 
 Inulin and related beneficial metabolites 
 Another dietary intervention that has gained interest as of late is 
consuming a diet that is enriched with fiber. According to the 2015-2020 Dietary 
Guidelines for Americans, the recommended intake amount of dietary fiber is 14 
grams per 1000 calories, but unfortunately most Americans are not consuming 
this quantity (<3%) [65, 66]. With increasing knowledge that the gut microbiota 
can influence multiple disease outcomes one particular class of fiber, prebiotics, 
have become a huge field to study. Prebiotics are any “selectively fermented 
ingredient that allows specific changes, both in the composition and/or activity in 
the gastrointestinal microflora, that confers benefits” [67]. When fermented by the 
microbiota in the colon, prebiotics yield metabolites known as short chain fatty 
acids (SCFAs) which can be absorbed and exert systemic actions, ultimately 
decreasing disease risk and outcomes [68].  
 Recent studies have shown that a critical component of the interplay that 
exists between the diet and the gut-liver axis involves SCFAs [69]. In the colon, 
the non-digestible prebiotic inulin is predominately fermented to a handful of 
SCFAs, acetate (82%), butyrate (12%) and propionate (6%) [70]. With regards to 
NAFLD, inulin can modulate risk and outcome by exerting anti-inflammatory and 
anti-oxidant effects. In one study, patients with NAFLD given a pro-biotic capsule 
plus Inulin showed improved inflammatory and oxidative parameters such as 
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decreased serum tumor necrosis factor-α (Tnf-α) and high-sensitive C-reactive 
protein (hs-CRP), providing a possible dietary treatment for the disease [71]. A 
similar response was also seen in mice fed atherogenic and steatosis producing 
HFD. Here, supplementation with a natural dietary supplement containing inulin 
prevented the development of NAFLD and atherogenic lesions by modulating 
signaling pathways involved in lipogenesis, lipid oxidation, and inflammation [72]. 
These new findings suggest that prebiotic supplementation with inulin may be an 
effective means to treat NAFLD, although data is still lacking and the related 
mechanisms remains unclear. 
Taking all this into account, it is clear that additional research is needed to 
determine the mechanisms by which pre-existing liver disease can influence the 
toxicity of PCBs. In addition, since modifications in diet and nutrition, such as 
increased consumption of green tea or prebiotic fibers, has been both historically 
and recently used as a therapeutic method to combat chronic inflammatory 
diseases and is dependent on a healthy liver, it is important to investigate to what 
extent can tea polyphenols and prebiotic fibers protect against the negative 
health effects caused by severe, end state liver disease. Hence, the objectives of 
this dissertation are outlined below.  
 
Scope of Dissertation 
 
 The overall objective of this project is determine the mechanisms by which 
a compromised liver can worsen PCB 126 toxicity and if beneficial nutrition can 
attenuate these effects. 
  
14 
 
  PCB-126 and the MCD diet were chosen to be utilized in the studies within 
this dissertation as a model pollutant and a model of severe fatty liver disease. 
PCB-126 has historically been implicated in negative human health effects and 
its structure is similar to many other pollutants, allowing for PCB-126 to be an 
ideal candidate for study. The MCD-diet causes the most severe stage of fatty 
liver disease and the mechanism by which steatosis is produced allows for 
ectopic fat accumulation to occur mainly in the liver, resulting in a lean mouse 
phenotype. These considerations are important because most liver disease 
studies focus on the beginning stages of liver disease when nearly 25% of those 
diagnosed with NAFLD eventually will present with NASH, the more severe 
disease phenotype [73]. Also, the effects of PCB-126 are dependent on its total 
body burden, with lean models possibly being more effective in studying lipophilic 
and dioxin-like pollutant toxicity.  
Our central hypothesis is that PCB-126 toxicity is worsened in the 
presence of a compromised liver and that nutritional intervention (green tea 
extract and inulin) can ameliorate these effects. As such, we will test our central 
hypothesis with the following specific aims: 
 
Specific Aim 1: Test the hypothesis that PCB-126 toxicity is worsened in the 
presence of a compromised liver in wild type C57BL/6 mice. 
 
Specific Aim 2: Test the hypothesis that the polyphenol-rich green tea extract 
(GTE) can protect against diet-induced liver injury in wild type C57BL/6 mice. 
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Specific Aim 3: Test the hypothesis that the prebiotic fiber inulin can attenuate 
steatohepatitis and PCB-126 toxicity in wild type C57BL/6 mice. 
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Chapter 2 Specific Aim 1: To test the hypothesis that PCB-126 toxicity is 
worsened in the presence of a compromised liver in wild type C57BL/6 
mice 
 
The data contained in this chapter has been previously published and permission 
for re-use of select text and figures has been obtained by the first author (B. 
Wahlang), the corresponding author (B. Hennig), and the publisher (Oxford 
University Press). Please see the below citation and appendix for additional 
details. 
 
Wahlang B, Barney J, Thompson B, Wang C, Hamad OM, Hoffman JB, et al. 
Editor's Highlight: PCB126 Exposure Increases Risk for Peripheral Vascular 
Diseases in a Liver Injury Mouse Model. Toxicol Sci. 2017;160:256-67. [18] 
 
Summary  
SCOPE: The liver plays a major role in overall metabolism, thus its proper 
function is crucial for overall health and protection against disease pathologies. 
Our lab has previously shown that PCB toxicity is exacerbated in mice with a 
dysfunctional liver. However how severe liver injury can influence PCB-126 
induced toxicity on other organ systems, such as the peripheral vasculature, and 
its associated disease states still needs to be examined. This study sought to 
investigate whether a compromised liver influenced PCB-126 toxicity on vascular 
inflammation in mice with severe liver injury.  
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METHODS AND RESULTS: In this 14-week study, male C57BL/6 mice were fed 
either a purified amino acid control diet (CD) or a methionine-choline deficient 
(MCD) diet with or without PCB-126 (0.5 mg/kg) exposure. Post euthanasia, 
tissues were collected and analyzed for histological, inflammatory, and metabolic 
parameters. PCB-126 caused steatosis irrespective of diet and mice fed the 
MCD-diet demonstrated steatosis. However, only in the MCD+PCB-126 group 
did we observe the presence of steatosis and fibrosis, indicative of 
steatohepatitis. Interestingly, the MCD+PCB-126 mice had increased hepatic and 
plasma inflammatory cytokine markers including Tumor necrosis factor alpha 
(Tnf-α) and macrophage chemoattractant protein-1/ chemokine (C-C motif) ligand 
2 (Mcp-1/Ccl-2). Interestingly, we also observed a significant increase in the 
hepatic and plasma levels of the proatherogenic biomarker trimethylamine-N-
oxide (TMAO) providing evidence of gut microbiota-liver interactions and 
vascular inflammation that is typically seen in atherosclerosis. 
 
CONCLUSIONS: The results presented in this study provides a novel link 
between a dysfunctional liver and PCB-126 toxicity on the liver and the peripheral 
vasculature, with implications of a role of the gut microbiota. This provides an 
important mechanistic role of dioxin-like pollutants, indicating their ability to 
contribute to the development and/or progression of inflammatory diseases via 
crosstalk with other organ systems. 
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Introduction 
 Exposure to environmental pollutants is a huge public health concern. 
Namely, a class of pollutants, the Polychlorinated Biphenyls (PCBs), have been 
implicated in many diseases states. PCBs were used predominately in industrial 
applications until their banishment in the 1970s in the USA and worldwide in 
2001 [41]. Although the production and use was banned, PCBs still persist in the 
environment because of their physical and chemical properties. Additionally, the 
major route of exposure to these chemicals is through the oral route via ingestion 
of contaminated food sources [45, 74, 75].  
 There are over 200 different congeners of PCBs. Their structure, most 
importantly their degree and position of chlorination on the biphenyl rings, 
determines their physical and chemical properties such as whether they present 
as a planar or co-planar configuration, their level of toxicity, and their mechanism 
of action. In particular co-planar, dioxin-like PCBs like PCB-126 can bind and 
activate the hepatic AhR, a transcription factor that can bind to the promoter 
regions in genes involved in detoxification and has been correlated with the 
pathology of a variety of chronic inflammatory diseases including obesity, 
cardiovascular diseases (CVDs), and liver diseases [35, 36, 38, 43, 44, 76-78].  
 Since most exposures of PCBs occurs through the oral route, it is 
important to consider how the liver influences its detoxification and overall 
toxicity. The liver is also the primary site of both xenobiotic and endobiotic 
metabolism hence its proper function is crucial. In addition to diet, exercise, and 
alcohol consumption, chemical toxins also can contribute to NAFLD 
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development. Importantly, liver disease can increase risk for other 
cardiometabolic diseases such as atherosclerosis and ligand activation of the 
AhR has been associated with both hepatic maladies and CVDs, suggesting AhR 
ligands could be a possible link between liver and cardiovascular diseases [79-
82]. However, the mechanisms linking the liver and the peripheral vasculature to 
inflammatory disease outcomes is limited [83, 84].  
 Taken altogether, the objective of this present study is to explore the 
effects that the dioxin-like, AhR ligand PCB-126 exerts on circulating 
inflammatory cytokines and vascular inflammation in the presence of a 
dysfunctional liver.  
 
Experimental design and methods 
Animals, diet, and experimental design 
All procedures and tests discussed in this study was approved by the 
University of Kentucky Institutional Animal Care and Use Committee. Animals 
were housed in a light and temperature controlled room on a 12 hour light/dark 
cycle with food and water given ad libitum. In this 14-week study, forty eight-
week old male C57Bl/6 mice were obtained from Taconic (Hudson, New York, 
USA) and divided into 4 experimental groups (n=10). Mice were fed either a 
purified amino acid control diet (CD; TD.94149; Envigo, Madison, Wisconsin, 
USA) or the liver injury producing methionine-choline deficient diet (MCD diet 
TD.90262, Envigo) and gavaged with either vehicle corn oil or PCB-126 in corn 
oil (0.5 mg/kg; AccuStandard, Connecticut, USA) at week 4 of the study, resulting 
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in the following groups (n=10): CD, CD+PCB-126, MCD, MCD+PCB-126. On 
week 1 of the study all mice were fed the CD and on week 2 respective groups 
were fed either CD or MCD diet. MCD-diet fed mice were reverted back to CD on 
week 5-6 of the study and then returned to MCD diet for the remainder of the 
study. This measure was taken to avoid excessive weight loss and subsequent 
noncompliance with the approved IACUC protocol.  Body weight was measured 
weekly and liver weights were taken post euthanasia. To assess for body 
composition, all mice were analyzed for lean and body fat mass using the 
EchoMRI (EchoMRI LLC, Houston, Texas, USA) at the completion of the study.   
 
Plasma and tissue collection 
Post euthanasia blood samples were collected, placed into tubes 
containing ethylenediaminetetraacetic acid (EDTA), briefly mixed, and 
centrifuged at 2000 g for 15 min at 4 C to separate blood plasma. Plasma and 
tissues samples were immediately frozen in liquid nitrogen and stored at -80°C 
until further analysis.  
 
Histological examination 
For histological examination, liver sections were fixed in 10% neutral 
buffered formalin and embedded in paraffin. Hepatic sections were stained with 
hematoxylin and eosin (H&E) and examined by light microscopy. All reagents 
were obtained Sigma Aldrich Corp. (St Louis, Missouri, USA). Images were 
captured using a high-resolution digital scanner at 10 and 40 magnification. 
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Using ImageJ software (NIH, Bethesda, Maryland, USA) fibrosis quantification 
was performed as previously described in Hadi et al [85]. 
 
Plasma Cytokine Measurements  
The Milliplex Map Mouse Adipokine Magnetic Bead Panel (Millipore Corp, 
Billerica, Massachusetts, USA) was used to measure plasma cytokines (tumor 
necrosis factor alpha (Tnf-α), interleukin-6 (IL-6), macrophage chemoattractant 
protein-1 [Mcp-1]), and plasminogen activator inhibitor-1 (PAI-1) while the 
Milliplex Map Mouse CVD Magnetic Bead Panel 1 was used to measure plasma 
CVD markers on the Luminex Xmap MAGPIX system (Luminex Corp, Austin, 
Texas, USA), following manufacturer’s instructions. Plasma aspartate 
transaminase (AST) and alanine transaminase (ALT) activity were measured with 
the Piccolo Xpress Chemistry Analyzer using Lipid Panel Plus reagent disks 
(CLIAwaived Inc., San Diego, California, USA).  
 
Measurement of trimethylamine-N-oxide (TMAO) 
Post euthanasia, methanol and acetonitrile was used to extract 
trimethylamine-N-oxide (TMAO) from 10 µl of plasma and ~50 mg liver tissues 
and respectively. HPLC electrospray ionization tandem mass spectrometry was 
used to analyze TMAO as described previously with slight modifications [86, 87]. 
Analysis was conducted using Shimadzu HPLC coupled with an AB Sciex 6500-
QTRAP hybrid linear ion trap triple quadrupole mass spectrometer in multiple 
reaction monitoring mode. For use as an internal standard and for relative 
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quantitation, mass labeled choline (d4-choline) was employed. TMAO was 
analyzed using a Primesep 100, 3 µm, 2.1 x 100 mm column (SIELC 
Technologies, Wheeling IL) and data were processed using ABSciex Multiquant 
software. 
 
mRNA extraction and PCR 
Total mRNA was extracted from mouse tissues samples using the TRIzol 
reagent (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA). The 
NanoDrop 2000/2000c (Thermo Fisher Scientific Inc.) using the NanoDrop 2000 
(Installation Version 1.6.198) software was utilized to determine RNA purity and 
quantity. Next, complementary DNA was synthesized from total mRNA using the 
QuantiTect Reverse Transcription Kit (Qiagen, Valencia, California, USA). 
Polymerase chain reaction (PCR) was performed on the CFX96 Touch Real-
Time PCR Detection System (Bio-Rad, Hercules, California, USA) using the 
Taqman Fast Advanced Master Mix (Thermo Fisher Scientific Inc.). All primers 
used in this study were acquired from Taqman Gene Expression Assays 
(Thermo Fisher Scientific Inc.). For liver gene expression the levels of mRNA 
were normalized relative to the amount of Actb with expressions levels of the 
CD+Vehicle experimental group set at 1. Gene expression levels were calculated 
using the 2-ΔΔCt method [88]. 
 
Statistical analysis 
All analyses were overseen by University of Kentucky biostaticians. 
Statistical analyses was conducted and graphs were plotted using GraphPad 
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Prism version 7.02 for Windows (GraphPad Software Inc., La Jolla, California, 
USA). Multiple group data were compared using 2-way ANOVA (column factor: 
diet and row factor: PCB-126) followed by Tukey’s post-hoc test for multiple 
comparisons. p < .05 was considered statistically significant. All data are 
expressed as mean ± SEM.   
 
Results 
2.1 Experimental design 
The experimental design for this study is presented in Figure 2.1. 
 
 2.2 PCB-126 Exposure Worsened Liver Injury Caused by MCD Feeding  
Firstly, in an effort to determine if the presence of a compromised altered 
PCB-126 toxicity, we examined hepatic liver sections for steatosis, inflammation, 
and fibrosis. Hepatic tissue samples were stained with H&E and assessed. It was 
demonstrated that mice MCD diet fed mice developed severe steatosis 
evidenced by ectopic fat infiltration in the hepatocytes, a major hallmark of 
steatosis. The MCD mice also exhibited indications of steatohepatitis, shown by 
the presence of inflammatory foci and fibrosis, the later confirmed by 
representative assessment via pico-sirius red staining of hepatic sections (Figure 
2.2). 
To gain a better understanding of the inflammatory and fibrotic response 
in the liver, PCR was conducted to assess the gene expression of the 
inflammatory markers Mcp1 (Ccl2) and Tnf-α, and the fibrotic markers PAI-1 and 
tissue inhibitor of metalloproteinases-1 (Timp1) (Figure 2.2). Remarkably, the 
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concomitant MCD+PCB-126 group displayed increased levels of expression of 
Mcp-1, Tnf-α, PAI-1, and Timp-1 in the liver when compared to all other groups. 
Additionally, the MCD+PCB-126 group exhibited higher plasma ALT and AST 
levels, a marker of liver injury. In fact, there was a significant interaction between 
diet and PCB-126 for elevated plasma ALT (p= .0005) (Figure 2.2).  
With regard to body weight (BW) and liver weight (LW), as anticipated 
both MCD groups demonstrated a decrease in the BW over the course of the 14-
week study when compared to the CD-fed mice. The LW to BW (LW/BW) ratio 
was also determined and the MCD+ PCB-126 mice presented with the largest 
LW/BW when compared to all other groups (Figure 2.2).  
 
2.3 PCB-126 Exposure in MCD fed mice Altered Hepatic Gene Expression of 
AhR Target Genes 
Since activation of AhR is the major cellular mechanism by which dioxin-
like PCBs exert their effects, the hepatic expression of genes related to PCB-126 
initiated AhR activation were measured. As anticipated, the gene of expression of 
the AhR target gene cytochrome P450 1A2 (Cyp1a2) was upregulated in both 
groups exposed to PCB-126 (Figure 2.3). Another AhR target, flavin-containing 
monooxygenase 3 (Fmo3), was also measured and an interesting finding in this 
study was the hepatic gene expression was solely increased in the MCD+PCB-
126 group. Since previous studies have shown that dioxin-like pollutants can 
increase hepatic Fmo3 expression, and this is correlated with an increased risk 
for CVD via TMAO synthesis, we also determined the hepatic and plasma TMAO 
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levels. Interestingly, hepatic gene expression of Fmo3 in addition to both hepatic 
and plasma TMAO levels were upregulated, and this result was only observed in 
the MCD+PCB-126 group. This finding is also important with regard to the gut-
liver axis, as TMAO production is a result of the actions of both the gut microbiota 
and the liver. 
 
2.3 PCB-126 Exposure Upregulated Markers of Peripheral Vascular Inflammation 
in MCD-Fed Mice  
To determine whether a compromised liver could influence PCB-126 
toxicity on other organ systems via systemic actions, we next examined the 
plasma profile of adhesion molecules and inflammatory cytokines (Figure 2.3). 
Interestingly, we observed an increase in markers of early endothelial cell injury 
in the MCD+PCB-126 group, as evidenced by increased levels of intercellular 
adhesion molecule 1 (Icam-1), platelet endothelial cell adhesion molecule 
(Pecam-1), E-selectin, P-selectin, thrombomodulin, and matrix metallopeptidase 
9 (proMMP-9), with a significant interaction between diet and PCB-126 for Icam-1 
(p = .002). With regards to peripheral vascular inflammation, similar to the results 
observed with markers of endothelial cell dysfunction, we also saw a significant 
increase in the systemic levels of inflammatory cytokines, Tnf-α and Mcp-1 in the 
MCD + PCB126 group. In fact, there was a significant interaction between diet 
and PCB-126 for both plasma Tnf-α and Mcp-1 (p < .0001).  
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Discussion 
 
 Since PCBs are persistent in the environment even though they were 
banned many years ago, studying the disease outcomes that are a direct result 
of and associated with the exposure to these chemicals is still necessary. It is 
well established that PCB-126 associated effects are driven by its activation of 
the AhR causing a cascade of events that ultimately leads to increased 
inflammation, disruption of the cellular redox status, liver injury, and other 
diseases [89-91]. Previous research in our lab showed that in the presence of a 
compromised liver, PCB toxicity was exacerbated by disrupting the energy 
homeostasis in NAFLD mice [19]. To further elicit how a compromised liver can 
specifically alter PCB-126 toxicity and influence cardio-metabolic disease 
outcomes, we examined the effects that PCB-126 exerted on the liver and 
peripheral vasculature.  
 Although PCB-126 alone was shown to induce ectopic fat accumulation in 
this study, PCB-126 in the presence of a compromised liver was the condition 
that contributed to the most pronounced hepatic and peripheral inflammation. 
The MCD+PCB-126 group exhibited worsened steatohepatitis as shown by 
hepatic H&E staining and increased gene expression of the inflammatory and 
fibrotic markers Mcp-1, Tnf-α, PAI-1, and Timp-1. This was also in conjunction 
with an increased LW/BW ratio and an increase in plasma ALT and AST, 
markers of toxicity and liver injury respectively. These findings suggest that in the 
presence of a compromised liver, PCB-126 induced hepatic toxicity is worsened.  
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In this study we also observed upregulated levels of the hepatic Fmo3, a 
downstream target of the AhR, in addition to increased levels of hepatic and 
plasma TMAO in MCD-fed mice exposed to PBC-126. Interestingly, TMAO is 
derived from the actions of both the gut-microbiota and the liver. The 
consumption of foods that is high in dietary choline and carnitine rich sources 
provides precursors that can be metabolized by the gut microbiota to 
trimethylamine (TMA). Next, hepatic FMO3 oxidizes TMA, forming TMAO. 
Interestingly, it has recently been shown in our lab that this pathway can be 
impacted by environmental factors, like dioxin-like PCBs as Petriello et al. 
showed that PCB-126 could possibly be a risk factor for CVDs because of its 
ability to upregulate Fmo3 [86]. The evidence linking dioxin-like PCBs, TMAO, 
and CVD risk is compelling with clinical studies showing that exposure to dioxin-
like pollutants may contribute to elevated levels of serum TMAO in addition to 
linking this small organic compound and CVD [37, 92, 93]. However, the 
mechanisms relating TMAO to CVD risk is still unclear, with others reporting 
conflicting findings showing that increased TMAO levels can slow aortic lesion 
formation [94].  
The findings in this present study raises two important questions. Firstly, if 
TMAO is derived from dietary choline and carnitine sources, how is it possible 
that we observed increases in the MCD+PCB-126 group when these mice were 
fed a diet absent of choline? A reasonable explanation is that the mice are using 
non-choline sources to form TMAO, however further investigation may be 
warranted. Secondly, since we observed such drastic effects of PCB exposure in 
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the MCD-fed mice with Fmo3 and TMAO levels and remembering that the TMAO 
molecule is derived from activities of the gut and the liver, what role does the gut 
microbiota play in the exacerbation of PCB-126 induced toxicity in this model? 
Future studies would need to be conducted to tease out the role that the gut-
microbiota plays in PCB-126 induced toxicity in mice with liver injury.   
Another interesting finding in this study was that the concomitant 
MCD+PCB-126 group exhibited a significant increase in both circulating 
inflammatory cytokines such as Tnf-α and Mcp-1 as well as early markers of 
peripheral vascular inflammation such as Icam-1, Pecam-1, E-selectin and 
thrombomodulin. The increase in plasma inflammatory makers supports the 
increase in hepatic inflammation reported above, showing that PCB-126 toxicity 
is worsening both hepatic and systemic inflammation. With regards to the 
upregulated markers vascular inflammation, we previously showed that PCB-126 
can induce endothelial cell dysfunction via a similar mechanism in vitro, thus this 
finding was important as it confirms a similar phenotype in vivo [95].  
Altogether, the findings in this study displayed that in the presence of a 
compromised liver PCB-126 toxicity is exacerbated, both hepatically and 
systemically. This study also provided a link between dioxin-like PCBs, the gut-
microbiota, and the liver, implicating the gut-liver axis and associated circulating 
metabolites like TMAO in CVD risk. This is especially important for individuals 
that have pre-existing liver conditions and are subsequently exposed to 
environmental pollutants, as they may have an increased risk for the 
development of other associated inflammatory diseases like CVD.  
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Figure 2.1 Experimental design. 
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Figure 2.1 Experimental design. Mice were divided into 4 study groups (n=10) 
based on diet type (CD or MCD) and PCB126 exposure. The timeline for diet 
separation and PCB exposure regimen are also outlined in the figure. Figure 
adapted from Wahlang et al. Toxicol Sci, 2017. 160(2): p. 256-267. 
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Figure 2.2. Effects of PCB126 exposure on steatosis and BW. 
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Figure 2.2. Effects of PCB126 exposure on steatosis and BW. A) H&E 
staining of hepatic sections established the occurrence of hepatocellular 
hypertrophy and steatosis in the MCD-fed groups. Each illustration is 
representative per treatment group B, Picrosirius red staining of hepatic sections 
indicated presence of fibrosis in the MCD groups. C, Hepatic mRNA expression 
for Ccl2/Mcp-1, Tnf-α, PAI-1 and Timp-1 were assessed. D, Plasma ALT and 
AST levels were measured using the Piccolo Xpress Chemistry Analyzer. 
Increase in BW with time for C57BL/6 (n=10) taken weekly from week 1-14. The 
% increase in BW gain with time was calculated and the BW at week 1 was taken 
as 100%. Livers were weighed at euthanasia and the liver to bodyweight ratio 
was calculated. Values are mean ±SEM, *p < .05 versus CD-fed mice, **p < .05 
versus CD-fed mice exposed to PCB126, #p < .05 versus MCD diet-fed mice, 
##p < .05 versus MCD-fed mice exposed to PCB126. Figure adapted from 
Wahlang et al. Toxicol Sci, 2017. 160(2): p. 256-267. 
  
33 
 
Figure 2.3. Effects of PCB126 on AhR target gene expression and TMAO 
levels. 
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Figure 2.3. Effects of PCB126 on AhR target gene expression and TMAO 
levels. A, Hepatic mRNA expression for AhR target genes Cyp1a2 and Fmo3 
were measured. B, TMAO was extracted from liver tissue and plasma and was 
measured using an ion trap triple quadrupole mass spectrometer. Figure adapted 
from Wahlang et al. Toxicol Sci, 2017. 160(2): p. 256-267. 
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Figure 2.4. PCB126 exposure increased circulating cytokine levels and 
markers of early vascular injury. 
 
  
  
36 
 
Figure 2.4. PCB126 exposure increased circulating cytokine levels and 
markers of early vascular injury. Plasma levels of Icam-1, Pecam-1, P-
Selectin, E-selectin, thrombomodulin, proMMP9, Tnf-α, Mcp-1 and PAI-1 were 
measured using the MAGPIX system. Values are mean ± SEM, *p < .05 versus 
CD-fed mice, **p < .05 versus CD-fed mice exposed to PCB126, #p < .05 versus 
MCD diet-fed mice, ##p < .05 versus MCD-fed mice exposed to PCB126. Figure 
adapted from Wahlang et al. Toxicol Sci, 2017. 160(2): p. 256-267. 
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Chapter 3 Specific Aim 2: Test the hypothesis that the polyphenol-rich 
green tea extract (GTE) can protect against diet-induced liver injury in wild 
type C57BL/6 mice 
 
Summary  
 
SCOPE: Nonalcoholic fatty liver disease (NAFLD) can impact gut microbiota 
health and vice versa. Our previous worked showed that PCB-126 toxicity was 
worsened in mice with pre-existing liver injury, with implications that the gut-
microbiota can possibly play a role in dioxin-like pollutant associated CVD risk 
[18]. A way to combat chronic inflammatory diseases is through nutritional 
modulation. Green tea extract (GTE) protects against NAFLD in multiple 
preclinical models, but its therapeutic effects are influenced by its bioavailability 
and no work in the more severe methionine-choline deficient (MCD) diet model 
has been completed. In addition, the interactions between MCD diet and GTE is 
not certain. Herein, we investigated whether GTE can protect against MCD-
induced hepatic toxicity and the development of NAFLD. 
 
METHODS AND RESULTS: In this 8 week study, mice were fed an amino acid 
control diet or a diet that induces liver injury in the absence or presence of GTE 
resulting in four experimental groups: control diet (CD), CD+ GTE, MCD, and 
MCD+ GTE. Histological parameters, inflammatory markers, GTE metabolism, 
and gut microbiota diversity were examined. Results indicated that MCD mice 
exhibited severe liver injury and gut dysbiosis and unexpectedly GTE had no 
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protective effects. Interestingly, MCD mice displayed differential epigallocatechin-
3-gallate (EGCG) metabolism at the hepatic and gut microbiota level which may 
alter polyphenol bioavailability and therapeutic potential.  
 
CONCLUSIONS: These results provide insight into how a dysfunctional liver and 
gut dysbiosis can alter polyphenol metabolism, possibly reducing its therapeutic 
efficiency. This is important for individuals with NAFLD that utilize beneficial 
polyphenols as a means of disease intervention.  
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Introduction  
The liver is the primary site for endobiotic and xenobiotic metabolism, 
hence its proper function is crucial for the body’s response to innate and extrinsic 
insults. Nonalcoholic fatty liver disease (NAFLD) is a major public health problem 
as its prevalence has steadily increased with an estimated 25% of the world’s 
population affected by this disease [7, 8]. NAFLD is the hepatic manifestation of 
metabolic syndrome and represents a spectrum of progressive diseases that 
ranges in severity from steatosis (fat accumulation) to steatohepatitis (steatosis 
and inflammation), to cirrhosis (advanced fibrosis), and eventually hepatocellular 
carcinoma or liver failure [7]. NAFLD pathophysiology is multifaceted and the 
causative mechanisms remain unclear, yet, a two or even multiple “hit” 
hypothesis has been proposed. This begins with an imbalance of the synthesis, 
influx, oxidation and export of hepatic lipids followed by a second “hit” initiated by 
oxidative stress, or gut-derived components that induces inflammation and/or 
fibrosis [14, 15]. In addition, the liver’s unique and significant blood supply via the 
portal and hepatic veins allows for anatomical and functional interactions with 
other organs and vice versa including the kidneys, the heart, and the 
gastrointestinal tract [96, 97]. This cross talk between organs is becoming a focus 
in disease development and progression with a new focus on the interactions 
between the gut and the liver, named the “gut-liver axis” being studied more in 
recent literature [97]. 
The gut microbiota is the diverse microbe population that resides in the 
gastrointestinal tract. It plays a major role in overall host health by aiding in 
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digestion, contributing to metabolism of dietary and host-derived molecules, 
combating other microorganism, and acting as a first line of defense to the 
external environment [98]. Additionally, the gut microbiota’s location makes it 
susceptible to dietary manipulation and current studies seek to identify 
techniques to alter disease risk using nutritional therapeutics targeting the gut 
[29, 30]. An imbalance of the intestinal flora, known as gut dysbiosis, is 
associated with disease development such as NAFLD [31]. Interestingly, the gut 
microbiota and the liver have been shown to participate in a partnership, known 
as the gut-liver axis, and has been associated with the development, 
progression, and exacerbation NAFLD [22].  
One way to combat the deleterious effects of fatty liver disease is by 
increasing consumption of beverages and foods that contain beneficial bioactive 
nutrients, dietary polyphenols. Tea is the 2nd most consumed beverage on the 
globe and in particular green tea and its major bioactive polyphenolic catechin 
epigallocatechin-3-gallate (EGCG) has been well studied as a therapeutic for 
NAFLD using in vivo models in recent years [59-61]. Although the mechanisms 
by which EGCG and other green tea polyphenols exert their protective effects 
are unclear, these compounds can decrease expression of hepatic transcription 
factors involved in downstream inflammatory responses [64] and increase 
expression of transcription factors involved in the activation of antioxidant 
response [63], resulting in anti-inflammatory and anti-oxidant properties 
respectively in rodent models of fatty liver disease. Still, these properties of 
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dietary polyphenols are subject to their bioavailability which is directly dependent 
on the activity of the liver.  
Since modifications in diet and nutrition, such as increased consumption 
of green tea, has historically been used as a method to combat disease and is 
dependent on a healthy liver, it is important to investigate the mechanisms by 
which tea polyphenols can protect against severe liver disease. Hence the 
objective of this present study was to investigate if GTE could protect against the 
hepatic toxicity associated with MCD-induced NAFLD. 
 
Experimental design and methods 
Animals, diet, and experimental design 
The animal protocol was approved by the University of Kentucky 
Institutional Animal Care and Use Committee. Animals were housed in a 
temperature- and-light controlled room on a 12 hour light/dark cycle with food 
and water ad libitum. Forty male C57BL/6 mice were purchased from Taconic 
(Hudson, NY, USA) and evenly divided into four study groups. Mice were fed 
either a purified amino acid control diet (CD; TD.130936; Envigo) or methionine-
choline deficient diet (MCD; TD.90262; Envigo) with or without supplementation 
of green tea extract (GTE; Sunphenon 30S-O,Taiyo, Minneapolis, MN, USA) at 
1% (w/w) in diet. On Week 1 mice were fed either CD or CD+GTE and beginning 
week 2 appropriate groups were fed MCD diet to induce liver injury, yielding the 
following 4 experimental groups: CD, CD+GTE, MCD, and MCD+GTE. All mice 
fed MCD diets were reverted back to their respective control diets for one week 
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(week 5) of this total 8 week study (Figure 3.1). This measure was taken to avoid 
excessive weight lost and subsequent non-compliance with the IACUC protocol. 
Bodyweight was measured weekly. At the completion of week 8, animals were 
humanely euthanized and tissues were harvested for mRNA or protein and 
stored at - 80 °C.  
 
Dosage Information 
GTE was supplemented in the animal diets at 1% wt/wt. The in vivo dose 
was chosen based on previous studies [99]. The amount of GTE per body weight 
in this study is comparable to approximately 4 cups of tea (~200 mL/cup) 
consumed per day in humans [100]. This dose is achievable through regular 
diets. 
 
Histological examination 
Hepatic tissues were fixed in 10% neutral buffered formalin and 
embedded in paraffin for histological assessment. Tissue sections were stained 
with hematoxylin and eosin (H&E) and examined by light microscopy. Images 
were captured using a high resolution digital scanner at 10x magnification. 
 
Metabolic profile assessment and urine collection 
At week 8 of the study, three mice from each group were randomly 
selected (n=3) and placed into metabolic cages individually (Techniplast, Exton, 
PA, USA). Urine samples were collected in the 24-hrs period and stored at -80°C 
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until analyzed. Three samples from each group were pooled proportionated to 
the urine volume of each mice. The pooled samples (~150 µL) were extracted 
using methanol. After centrifugation, the supernatant was dried under nitrogen 
flow. The residue was resolved in a mixed solution of acetonitrile: water (9:1, v/v), 
and 5 μL of sample was injected for LC-MS analysis. An ultra-high performance 
liquid chromatography Q-Exactive mass spectrometer (Thermo Fisher Scientific, 
San Jose, CA) was used for sample detection. Chromatographic separation was 
performed on a reversed phase Kinetex C18 column (2.6 mm × 100 mm, 2.1 μm, 
Phenomenex, USA). Mobile phases were composed of acetonitrile (A) and water 
(B), both containing 0.1% formic acid. The column temperature was maintained 
at 40°C, and the flow rate was set to 0.4 ml/min. Mass spectrometric detection 
was performed by electrospray ionization in positive ionization mode with source 
voltage maintained at 4.3 kV. The capillary temperature, sheath gas flow and 
auxiliary gas flow were set at 330°C, 35 arb and 12 arb, respectively. Full-scan 
MS spectra (mass range m/z 75 to 1000) were acquired with resolution R = 
70,000 and AGC target 1e6. MS/MS fragmentation was performed using high-
energy C-trap dissociation with resolution R = 35,000 and AGC target 2e5. The 
stepped normalized collisional energy scheme was set at 30, 40, and 50. Raw 
data files acquired in full scan-ddMS2 mode were imported into Compound 
Discoverer™ software (v. 2.1; Thermo Fisher Scientific) to identify EGCG, ECG, 
EGC, and EC metabolites respectively. The software detects chromatographic 
peaks, and the mass of the corresponding compound is compared with a list of 
generated theoretical metabolites. Potential metabolites were proposed based on 
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exact mass, MS2 fragmentation, isotopic pattern and retention time with respect 
to the parent compound.  
 
Blood collection and plasma protein quantification  
Post euthanasia blood samples were collected, mixed briefly with EDTA, 
and centrifuged at 2000 g for 15 minutes at 4 °C to isolate plasma. Plasma 
samples were frozen in liquid nitrogen and stored at - 80 °C until further 
processing. Plasma alanine transaminase (ALT) and aspartate transaminase 
(AST) levels were measured using the Piccolo Xpress Chemistry Analyzer using 
Lipid Panel Plus reagent disks (CLIAwaived Inc., San Diego, CA, USA). 
 
RNA extraction and quantitative real-time PCR 
Intestinal and liver samples were homogenized and total mRNA was 
isolated with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). mRNA purity and 
quantity were determined using the NanoDrop 2000 spectrophotometer (Thermo 
Fisher Scientific Inc., Waltham, MA, USA) using the NanoDrop 2000 version 
1.6.198 and cDNA was synthesized from total RNA using the QuantiTect 
Reverse Transcription Kit (Qiagen, Valencia, CA, USA). PCR was performed 
using the Taqman Fast Advanced Master Mix (Thermo Fisher Scientific Inc.) on 
the CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA, 
USA). All primers were acquired from Taqman Gene Expression Assays (Thermo 
Fisher Scientific Inc.). The mRNA levels were normalized relative to the quantity 
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of Actb for intestinal samples or Rn18s for liver samples and levels of gene 
expression were calculated using the 2−ΔΔCt method.[88] 
 
Cecum DNA extraction and 16S rRNA sequencing for bacterial taxonomy  
At the conclusion of the study, cecum samples were sent to Argonne 
National Laboratory. DNA extraction and 16S sequencing was performed by the 
Environmental Sample Preparation and Sequencing Facility (ESPSF) and 
analyzed by the Quantitative Insights into Microbial Ecology (QIIME) program. 
DNA extraction was conducted using the PowerSoil 96-well DNA Isolation Kit 
(MoBio, Carlsbad, CA, USA) according to the manufacturer’s protocol with the 
addition of a 65°C heating step after solution C1 addition. The protocol used for 
the production of the PCR amplicon library, amplicon quantification and 
sequencing, and operation taxonomic units (OTUs) selection and filtration is 
outlined in Petriello, M.C. and Hoffman, J.B., et al.[28]  
 
Statistical Analysis  
A University of Kentucky biostatistician was consulted for data analysis. 
For cecum bacterial phyla tables, for each type of bacteria, relative abundance 
means, and standard errors were calculated for each of the four groups. Next, a 
full factorial two-way beta regression model was fit using the “betareg” package 
in R, analyzing differences in relative bacterial abundance between CD and MCD 
diets and in the presence or absence of green tea extract supplements. 
Reported p-values come from a likelihood ratio test of the overall model fit. All 
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analyses were completed in R, version 3.4.4 (R Foundation for Statistical 
Computing; Vienna, Austria). For all other data, statistical analyses were 
conducted and graphs were plotted using GraphPad Prism version 7.02 for 
Windows (GraphPad Software Inc., La Jolla, CA, USA). Data are expressed as 
mean ± SEM. Multiple group data was compared using Two Way ANOVA 
(column factor: diet row factor: GTE) followed by the Tukey’s post-hoc test for 
multiple comparisons. For all data presented in this chapter, p-values < 0.05 was 
considered statistically significant.  
 
Results 
3.1 Experimental design 
The experimental design for this study is presented in Figure 3.1. 
 
3.2 GTE does not protect against MCD-induced hepatic steatosis and 
inflammation 
In an effort to examine the effect that GTE supplementation had on MCD-
induced liver injury, hepatic steatosis was assessed histologically and 
inflammation assessed via histology, hepatic gene expression, and plasma 
cytokine measurements. MCD diet feeding resulted in severe hepatic steatosis 
and inflammation, consistent with previous studies. Additionally, H&E staining 
revealed an increase in ectopic fat deposition in the hepatocytes of the MCD 
groups in addition to the presence of inflammatory foci, an indication of 
steatohepatitis (Figure 3.2). This was further proven with a significant increase in 
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macrovesicular fat content in all MCD fed mice as determined by a liver 
pathologist (Figure 3.2). We also observed a decrease in the liver weight (LW) of 
mice fed MCD diet when compared to both control groups (Figure 3.2).  
With regards to inflammation, the hepatic mRNA expression was 
determined by qPCR analysis. The gene expression of inflammatory markers 
including Tumor necrosis factor alpha (Tnf-α), C-C motif chemokine ligand 2 
(Ccl2) also called Monocyte chemoattractant protein-1 (Mcp1), and Plasminogen 
activator inhibitor-1 (Pai-1) were all increased in mice with liver injury, and GTE 
supplementation did not have any protective effects (Figure 3.2). Furthermore, 
liver injury was further confirmed by significantly increased amounts of ALT in the 
plasma of MCD fed mice compared to both CD fed groups was observed in 
addition to an increase in plasma AST in MCD groups when compared to the 
mice fed CD only (Figure 3.2). Taken altogether, this data ascertains that MCD 
diet feeding contributed to liver injury by increased hepatic fat accumulation and 
inflammation and GTE supplementation had no significant effects on any 
outcomes associated with the development and progression of hepatic steatosis 
or inflammation. 
 
3.3 Liver injury alters hepatic and gut microbiota catalyzed green tea metabolite 
profile 
Since we did not see any GTE protection from MCD-induced liver injury, 
we then sought to understand whether there were alterations in GTE metabolism 
due to this severe disease state. We examined the GTE urine metabolite profile 
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at the end of the study. At week 8, mice from each group (n=3) were placed into 
solo urine collection cages for 24 hours and the GTE metabolite profile was 
measured via LC-MS. Interestingly, mice with a dysfunctional liver exhibited an 
increase in the urine excretion of parent compounds EGCG and ECG while on 
the contrary, these mice displayed a decrease in the corresponding metabolites 
EGC and EC respectively (Figure 3.3). Furthermore, mice with liver injury 
demonstrated an increase in overall glucuronides and sulfation conjugation GTE 
metabolites and a decrease in the overall methylation (Figure 3.3 and Table 3.1). 
In addition, a significant decrease in the gut microbiota catalyzed ring fission 
metabolites was seen in MCD diet fed mice, with 5-dihydroxyphenyl valeric acid 
and its conjugates being the major metabolites (Table 3.2).   
 
3.4 Liver injury modifies expression of hepatic, not intestinal, phase 2 
metabolizing enzymes and transporters 
To further delineate the mechanisms associated with the GTE metabolism 
changes that were observed in mice with liver injury, we next examined the gene 
expression of conjugation enzymes and membrane transporters in the intestines 
and the liver. In the intestines, there were no changes in the gene expression of 
catechol-O-methyltransferase (Comt), UDP-glucuronosyltransferase 1-1 
(Ugt1a1), or sulfotransferase family 1b member 1 (Sult1b1) which translate to 
proteins that play major roles in metabolism via transfer of a methyl group, 
glucuronic acid group, or a sulfate group respectively (Figure 3.4). In addition, 
there was no observed changes in the intestinal gene expression of the 
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transporter ATP-binding cassette sub-family C member 2/ multidrug resistance-
associated protein 2 (Abcc2/Mrp2). Similar to the intestinal gene expression, 
hepatic Comt and Ugt1a1 were unchanged. However, hepatic gene expression 
of sulfotransferase family 1a member 1 (Sult1a1) and the transporter Abcc2/Mrp2 
was significantly increased in the MCD+GTE mice when compared to all other 
groups. We also observed increased levels of the transporter ATP-binding 
cassette sub-family C member 2/ multidrug resistance-associated protein 1 
(Abcc1/Mrp1) gene in both MCD groups (Figure 3.4).  
 
3.5 MCD-induced liver injury alters the bacterial phyla profile and the FB ratio 
Recent studies have begun to delineate the mechanisms by which the gut-
liver axis can contribute to disease pathology and influence host health. To 
further understand the role that the gut-liver axis can plays in NAFLD 
development and progression as well as the effects it can exert on nutrient 
metabolism, 16S rRNA sequencing was conducted at the completion of the study 
to quantify bacterial populations. Cecal samples were utilized as the cecum 
serves as the principal site of bacterial metabolism and fermentation, in addition 
to having the greatest abundance of microbiota. We observed a major shift in the 
microbiota profile of MCD diet fed mice (Table 3.3).The MCD groups exhibited 
alterations in the taxonomic composition of the cecal microbiota at the phylum 
level at sacrifice (Figure 3.5). When compared to all other groups, the MCD+GTE 
group exhibited an increase the alpha diversity (Shannon diversity index), a 
measure of gut microbiota diversity within a sample and measures the number of 
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different microbes (richness) and the distribution of different microbes (evenness) 
(Figure 3.5). With regard to the Firmicutes/Bacteroidetes (FB) ratio the MCD 
group’s ratio was increased when compared to both control groups and GTE 
supplementation decreased this effect, although this was not statistically 
significant (p=0.08) (Figure 3.5).  
 
3.6 MCD fed mice exhibits gut dysbiosis via alterations in the cecal bacterial 
profile  
Interestingly, at the phyla level, MCD-induced liver injury significantly 
increased the abundance of the Tenericutes bacterial phyla (Figure 3.6). More 
specifically at the corresponding order level, the bacteria RF39 was increased in 
MCD fed mice. Moreover, the phyla Verrucomicrobia was significantly increased 
in both MCD diet fed groups and GTE supplemented groups, and this was 
accompanied by an increase in the corresponding genus Akkermansia (Figure 
3.6). We also observed a decrease in the abundance of the bacterial phyla 
Bacteroidetes and its parallel genus Parabacteroides in the MCD group when 
compared to both control groups (Figure 3.6). These findings showed that MCD 
diet can alter cecal bacterial profiles, causing gut dysbiosis.   
 
Discussion 
NAFLD is still a major public health concern, with nearly one-fourth of the 
world’s inhabitants suffering from this disease. The liver is a vital organ in the 
body and proper metabolism and overall host health is dependent on it being in a 
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healthy state. One factor that can contribute to the development and/or 
progression of NAFLD is the secretion of gut-derived components that act on the 
liver as a result of gut dysbiosis [22]. A way to combat the deleterious effects 
seen with NAFLD is through changes in diet and lifestyle with recent clinical 
guidelines suggesting an increase consumption of foods and beverages rich in 
naturally occurring antioxidant components as a way to prevent and treat NAFLD 
[101].  
Green tea has historically been used to prevent or attenuate multiple 
chronic inflammatory disease including NAFLD, but it’s important to remember 
that its therapeutic capabilities may be dependent on its metabolism and 
bioavailability [62, 102]. Hence, the primary aim of this study was to investigate if 
GTE could protect against the hepatic toxicity associated with MCD-induced 
NAFLD. 
Consistent with our previous studies and the work of others, we saw that 
MCD diet feeding induced steatohepatitis by increasing hepatic fat accumulation 
and inflammation [18, 19, 103]. Steatosis was evidenced by H&E staining and an 
increase in the macrovesicular fat content. There was also a significant decrease 
in the LW of MCD groups versus both CD groups. This was accompanied by an 
increase in inflammation as seen by increased gene expression of the hepatic 
inflammatory markers TNF-α, Ccl2, and Pai-1 in addition to a significant increase 
in plasma ALT in MCD diet fed mice when compared to CD groups. In addition, 
we observed an increase in the plasma levels of AST in MCD mice when 
compared to the CD only fed group was also observed. These result were 
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anticipated as the MCD diet is a highly utilized and robust rodent model of 
NAFLD, with continual feeding causing fat accumulation and inflammation and/or 
fibrosis, leading to the end stage of fatty liver disease known as NASH [104]. 
However what was unexpected was the finding that GTE supplementation did not 
protect against MCD-induced hepatic steatosis or inflammation.  
Nutritional intervention has been historically used as a natural and feasible 
method to combat chronic, inflammatory disease. However, because most 
endogenous and exogenous components are metabolized by the intestines and 
in the liver, it is important to investigate how a dysfunctional liver can alter the 
metabolism of beneficial dietary components that are intended to prevent or 
reduce disease risk. Since we observed hepatic injury, we then sought to 
understand how this phenotype could influence the metabolism, and possibly the 
lack of protection, of the GTE. 
In this study, MCD fed mice exhibited a significant increase in the urine 
excretion of both the parent compounds EGCG and ECG while their respective 
metabolites EGC and EC were decreased. Others have reported a similar result 
with Chen et al. reporting that obese rats had higher excretion of EGCG and 
ECG and the absence of EGC and EC in the feces after oral administration of tea 
polyphenols [105]. The increased EGCG and ECG excretion may be dependent 
on multiple mechanisms, including the efflux by transporters such as Abcc2. 
Abcc2 is a major efflux transporter that resides on the canalicular membrane of 
hepatocytes and is responsible for substrate transport, including elimination of 
conjugated substances [106, 107]. Furthermore, it has been reported that during 
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the progression of human NAFLD Abcc1 and Abcc2 expression is increased 
[108]. Interestingly, Hong et al. concluded from studies in a canine kidney cell 
line that EGCG and its metabolites can be substrates for Abcc2 [109]. It is 
reasonable to suggest that this observation is related to the increase of EGCG in 
the urine of MCD fed mice. The decrease in the presence of EGC and EC may 
be because of its metabolism into low molecular-weight phenolic acids, as seen 
in other studies in rats [105].  
An interesting finding in this study related to GTE metabolism was the 
observed increase in GTE sulfation metabolites. To further explain this increase, 
the hepatic gene expression of the conjugation enzyme Sult1a1 was measured 
via qPCR. Sult1a1 is a major drug-metabolizing enzyme that catalyzes the 
sulfate conjugation to many endogenous and exogenous compounds. We 
observed a significant increase in the gene expression of Sult1a1 solely in the 
MCD+GTE group which could support the increase we saw in sulfate conjugated 
GTE metabolites that was seen in MCD diet fed mice. In this study, we also 
observed an increase in glucuronidation GTE metabolites in MCD diet fed mice. 
We followed up with this finding by examining the gene expression of Ugt1a1 in 
the intestines and the liver. Surprisingly, the expression of Ugt1a1 was 
unchanged in both the intestines and the liver. Further analysis looking into other 
glucuronidation enzymes will need to be conducted to determine why this 
increase was observed. 
Another major metabolic change that was seen was the significant 
decrease in GTE methylation metabolites in the urine. Comt is one of several 
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enzymes that is responsible for the degradation of catecholamines such as 
epinephrine and dopamine and any other compounds that have a catechol entity. 
Many drugs have been developed to target this enzyme. The presence of a 
catechol-like structure, like that seen in EGCG and ECG as well as their resulting 
metabolites, makes these compounds susceptible to methyl addition by both 
rodent and human Comt [110, 111].  
We observed an increase in methylation GTE metabolites in the urine of 
mice with liver injury, however there was no change in the hepatic gene 
expression of Comt in any of the experimental groups. Interestingly, the Comt 
enzyme activity is dependent on the donation of a methyl group from S-adenosyl 
methionine (SAM) and we (unpublished data) have shown that in MCD diet fed 
mice, the SAM cofactor was depleted. This is plausible, as the MCD diet lacks 
the essential amino acid methionine, which is involved in SAM synthesis [50-52]. 
In fact, other models of NAFLD, including high fat diet feeding, also shows a 
significant reduction in the SAM co-factor [112]. We believe this explains why we 
observed a decrease in methylation GTE metabolites without an expressional 
change in the intestinal or hepatic gene expression of Comt.  
 Furthermore, liver injury in mice fed MCD diet also had a significant 
decrease in the gut microbiota catalyzed ring fission metabolites. Specifically, the 
metabolite 5-dihydroxyphenyl valeric acid and its conjugates were the major 
metabolites, as seen by an increase in the peak area. Meng et al. reported that in 
healthy humans and rodents administered green tea or ECGC, the ring fission 
metabolites were identified by LC-MS at significant amounts in the plasma and in 
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the urine, implicating the intestinal microbiota in green tea and EGCG 
metabolism [113]. However, research investigating the gut microbiota catalyzed 
metabolism of GTE and its major polyphenolic constituents is still lacking. 
After confirming liver injury in mice fed MCD diet and that GTE displayed 
no protection against hepatic injury with a major shift in the hepatic and gut 
microbiota catalyzed metabolic profile, we then sought to understand the role of 
the gut microbiota in the observed metabolic changes and overall host health. 
Remarkably, alterations in the cecal gut microbiota profile was seen in mice fed 
the MCD diet. In comparison to all other groups, the alpha diversity was 
increased in the MCD+GTE mice. In particular, we observed no changed in the 
Firmicutes phylum in both MCD groups when compared to the CD only fed 
group. With regard to the Bacteroidetes phylum, we observed a decrease in mice 
fed the MCD diet only when compared to the CD only fed group. This finding was 
also seen in human studies of patients with NAFLD with Mouzaki et al. reporting 
a decrease in fecal Bacteroidetes [20]. However, when examining these two 
phyla, the ratio of Firmicutes to Bacteroidetes (FB ratio) may be a more important 
parameter to assess as an increase in the FB ratio has been positively correlated 
with NAFLD in addition to an increased susceptibility to oxidative stress and 
inflammation [114]. In this study, we observed a significant increase in this ratio 
in mice with liver injury and GTE supplementation seemed to attenuate these 
effects (p=0.08). This suggests that MCD feeding exerts some negative effects 
on the intestinal gut flora and that GTE exerts some protective effects, although 
the finding in this study was statistically insignificant.   
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Additionally, MCD feeding significantly increased the Tenericutes phylum 
as well the corresponding order RF39. In recent literature, Rau et al. reported a 
significant decrease in the fecal abundance of Tenericutes in human patients 
with NASH while Ye, Li, and Wu et al. reported that mice fed MCD diet showed a 
significant increase in Tenericutes as compared to that of CD mice [115, 116]. 
However, the Tenericutes phyla has been poorly studied and there is a sufficient 
lack of evidence and information investigating this phyla in metabolic syndrome 
and fatty liver disease.  
In conclusion, our current study demonstrates that GTE cannot protect 
against severe liver injury as seen in this MCD mouse model. However, diet-
induced liver injury in conjunction with guy dysbiosis can alter the metabolite 
profile of GTE, possibly impacting the protective properties of GTE. The findings 
of this study has translational implications as proposed interventions for 
individuals with liver disease typically includes changes in diet and lifestyle, 
particularly by encouragement to increase consumption of nutrient rich and lower 
fat foods. Future studies are needed to determine the causative mechanisms by 
which the gut-liver axis can contribute to altered nutrient metabolism and how 
this can influence overall health in humans. 
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Table 3. 1.Summary of phase II GTE metabolites in mice urine. 
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Table 3. 1. Summary of phase II GTE metabolites in mice urine. At week 8, 
mice from each group (n=3) were placed into solo metabolic cages and urine 
samples were collected over 24 hours. Pooled urine was extracted using 
methanol and analyzed by UHPLC/Q Exactive MS. Data was processed by 
CompoundDiscover and LC-MS peak area for each metabolite was calculated. 
J.B and P.D contributed equally to sample collection. P.D. analyzed data and 
made figure. 
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Table 3. 2. Gut microbiome catalyzed GTE metabolites in mice urine. 
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Table 3. 2. Gut microbiome catalyzed GTE metabolites in mice urine. At 
week 8, mice from each group (n=3) were placed into solo metabolic cages and 
urine samples were collected over 24 hours. Pooled urine was extracted using 
methanol and analyzed by UHPLC/Q Exactive MS. Data was processed by 
CompoundDiscover. The major metabolic pathway catalyzed by the gut 
microbiota is ring fission leading to the formation of 5-dihydroxyphenyl valeric 
acid and its conjugates. J.B and P.D contributed equally to sample collection. 
P.D. analyzed data and made figure. 
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Table 3. 3. MCD-induced liver injury alters the cecum bacterial profile. 
Bacteria Category CD CD+GTE MCD MCD+GTE 
Overall 
Model 
p-Value 
Phyla 
Unassigned_Other 0.0041 
(0.0032) 
0.0017 
(0.0002) 
0.0142 
(0.0084) 
0.0038 
(0.0025) 
0.8518 
Actinobacteria 0.0006 
(0.0003) 
0.0005 
(0.0001) 
0.0051 
(0.0013) 
0.0051 
(0.0031) 
0.0002 
Bacteroidetes 0.2226 
(0.0448) 
0.3234 
(0.0329) 
0.0592 
(0.0194) 
0.1251 
(0.0312) 
<0.0001 
Cyanobacteria 0.0138 
(0.0004) 
0.0164 
(0.0007) 
0.0142 
(0.0009) 
0.0139 
(0.0003) 
0.0084 
Deferribacteres 0.0303 
(0.0095) 
0.0562 
(0.0052) 
0.0261 
(0.0087) 
0.0412 
(0.0120) 
0.0188 
Firmicutes 0.6858 
(0.0600) 
0.4338 
(0.0390) 
0.6507 
(0.0361) 
0.5914 
(0.0484) 
0.0014 
Proteobacteria 0.0193 
(0.0073) 
0.0028 
(0.0024) 
0.0203 
(0.0089) 
0.0118 
(0.0037) 
0.0337 
TM7 0.0135 
(0.0002) 
0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0135 
(0.0001) 
0.0132 
Tenericutes 0.0075 
(0.0018) 
0.0077 
(0.0021) 
0.0454 
(0.0106) 
0.0369 
(0.0071) 
<0.0001 
Verrucomicrobia 0.0289 
(0.0172) 
0.1706 
(0.0339) 
0.1781 
(0.0362) 
0.1835 
(0.0385) 
<0.0001 
Class 
Actinobacteria_Coriobacteriia 0.0137 
(0.0003) 
0.0137 
(0.0001) 
0.0158 
(0.0006) 
0.0143 
(0.0003) 
0.0006 
Bacteroidetes_Bacteroidia 0.2226 
(0.0448) 
0.3234 
(0.0329) 
0.0591 
(0.0194) 
0.1251 
(0.0312) 
<0.0001 
Cyanobacteria_4C0d.2 0.0138 
(0.0004) 
0.0164 
(0.0007) 
0.0133 
(0.0001) 
0.0136 
(0.0002) 
<0.0001 
Deferribacteres_Deferribacteres 0.0303 
(0.0095) 
0.0562 
(0.0052) 
0.0261 
(0.0087) 
0.0412 
(0.0120) 
0.0188 
Firmicutes_Bacilli 0.0136 
(0.0069) 
0.0012 
(0.0005) 
0.2424 
(0.0399) 
0.0913 
(0.0201) 
<0.0001 
Firmicutes_Clostridia 0.6425 
(0.0594) 
0.4092 
(0.0377) 
0.3451 
(0.0308) 
0.4322 
(0.0471) 
<0.0001 
Proteobacteria___Deltaproteobacteria 0.0311 
(0.0071) 
0.0155 
(0.0023) 
0.0147 
(0.0006) 
0.0132 
(0.0000) 
0.01 
Proteobacteria_Gammaproteobacteria 0.0008 
(0.0003) 
0.0004 
(0.0001) 
0.0167 
(0.0073) 
0.0115 
(0.0037) 
0.0021 
Tenericutes_Mollicutes 0.0075 
(0.0018) 
0.0077 
(0.0021) 
0.0454 
(0.0106) 
0.0369 
(0.0071) 
<0.0001 
Verrucomicrobia_Verrucomicrobiae 0.0289 
(0.0172) 
0.1706 
(0.0339) 
0.1781 
(0.0362) 
0.1835 
(0.0385) 
<0.0001 
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Table 3. 3. (Continued).  
Bacteria Category CD CD+GTE MCD MCD+GTE 
Overall 
Model 
p-Value 
Order 
Actinobacteria___Coriobacteriales 0.0137 
(0.0003) 
0.0137 
(0.0001) 
0.0158 
(0.0006) 
0.0143 
(0.0003) 
0.0006 
Bacteroidetes____Bacteroidales 0.2226 
(0.0448) 
0.3234 
(0.0329) 
0.0591 
(0.0194) 
0.1251 
(0.0312) 
<0.0001 
Cyanobacteria_4C0d.2_YS2_ 0.0303 
(0.0095) 
0.0562 
(0.0052) 
0.0261 
(0.0087) 
0.0412 
(0.0120) 
0.0188 
Deferribacteres__Deferribacterales 0.0140 
(0.0006) 
0.0132 
(0.0000) 
0.0258 
(0.0067) 
0.0134 
(0.0001) 
0.0322 
Firmicutes__Bacillales 0.0109 
(0.0053) 
0.0009 
(0.0004) 
0.0271 
(0.0105) 
0.0135 
(0.0075) 
0.0043 
Firmicutes___Lactobacillales 0.0018 
(0.0012) 
0.0003 
(0.0000) 
0.2021 
(0.0378) 
0.0775 
(0.0159) 
<0.0001 
Firmicutes___Turicibacterales 0.6425 
(0.0594) 
0.4092 
(0.0377) 
0.3451 
(0.0308) 
0.4322 
(0.0471) 
<0.0001 
Firmicutes___Clostridiales 0.0311 
(0.0071) 
0.0155 
(0.0023) 
0.0147 
(0.0006) 
0.0132 
(0.0000) 
0.01 
Proteobacteria_Desulfovibrionales 0.0008 
(0.0003) 
0.0004 
(0.0001) 
0.0167 
(0.0073) 
0.0115 
(0.0037) 
0.0025 
Proteobacteria__Enterobacteriales 0.0075 
(0.0018) 
0.0074 
(0.0021) 
0.0448 
(0.0106) 
0.0358 
(0.0073) 
<0.0001 
Tenericutes__RF39 0.0289 
(0.0172) 
0.1706 
(0.0339) 
0.1781 
(0.0362) 
0.1835 
(0.0385) 
<0.0001 
Verrucomicrobia_Verrucomicrobiales 0.0137 
(0.0003) 
0.0137 
(0.0001) 
0.0158 
(0.0006) 
0.0143 
(0.0003) 
0.0006 
Family 
Actinobacteria_Coriobacteriaceae 0.2106 
(0.0421) 
0.3195 
(0.0307) 
0.0573 
(0.0195) 
0.1169 
(0.0273) 
<0.0001 
Bacteroidetes_Porphyromonadaceae 0.0138 
(0.0004) 
0.0164 
(0.0007) 
0.0133 
(0.0001) 
0.0136 
(0.0002) 
<0.0001 
Bacteroidetes____Rikenellaceae 0.0303 
(0.0095) 
0.0562 
(0.0052) 
0.0261 
(0.0087) 
0.0412 
(0.0120) 
0.0188 
Deferribacteres__Deferribacteraceae 0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0134 
(0.0001) 
0.0132 
(0.0000) 
0.0012 
Firmicutes____Bacillaceae 0.0140 
(0.0006) 
0.0132 
(0.0000) 
0.0254 
(0.0066) 
0.0133 
(0.0001) 
0.0384 
Firmicutes____Staphylococcaceae 0.0056 
(0.0025) 
0.0008 
(0.0004) 
0.0107 
(0.0028) 
0.0132 
(0.0075) 
0.0071 
Firmicutes____Lactobacillaceae 0.0018 
(0.0012) 
0.0003 
(0.0000) 
0.2021 
(0.0378) 
0.0775 
(0.0159) 
<0.0001 
Firmicutes____Turicibacteraceae 0.0225 
(0.0192) 
0.0024 
(0.0013) 
0.1081 
(0.0224) 
0.0543 
(0.0138) 
<0.0001 
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Table 3. 3. (Continued).  
Bacteria Category CD CD+GTE MCD MCD+GTE 
Overall 
Model 
p-Value 
Firmicutes____Clostridiaceae 0.0841 
(0.0141) 
0.0700 
(0.0053) 
0.0545 
(0.0074) 
0.0990 
(0.0188) 
0.0344 
Firmicutes____Lachnospiraceae 0.0134 
(0.0002) 
0.0132 
(0.0001) 
0.0142 
(0.0002) 
0.0132 
(0.0000) 
0.0002 
Firmicutes___Peptostreptococcaceae 0.2583 
(0.0531) 
0.1932 
(0.0368) 
0.0959 
(0.0209) 
0.1597 
(0.0212) 
0.0112 
Firmicutes____Ruminococcaceae 0.0136 
(0.0002) 
0.0135 
(0.0001) 
0.0134 
(0.0001) 
0.0144 
(0.0004) 
0.0019 
Firmicutes____.Mogibacteriaceae. 0.0311 
(0.0071) 
0.0155 
(0.0023) 
0.0147 
(0.0006) 
0.0132 
(0.0000) 
0.0099 
Proteobacteria__Desulfovibrionaceae 0.0008 
(0.0003) 
0.0004 
(0.0001) 
0.0167 
(0.0073) 
0.0115 
(0.0037) 
0.0025 
Proteobacteria__Enterobacteriaceae 0.0289 
(0.0172) 
0.1706 
(0.0339) 
0.1781 
(0.0362) 
0.1835 
(0.0385) 
<0.0001 
Verrucomicrobia_Verrucomicrobiacea 0.0137 
(0.0003) 
0.0137 
(0.0001) 
0.0158 
(0.0006) 
0.0143 
(0.0003) 
0.0006 
Genus 
Actinobacteria____Adlercreutzia 0.2106 
(0.0421) 
0.3195 
(0.0307) 
0.0573 
(0.0195) 
0.1169 
(0.0273) 
<0.0001 
Bacteroidetes____Parabacteroides 0.0248 
(0.0050) 
0.0169 
(0.0038) 
0.0145 
(0.0007) 
0.0171 
(0.0024) 
0.2116 
Deferribacteres____Mucispirillum 0.0303 
(0.0095) 
0.0562 
(0.0052) 
0.0261 
(0.0087) 
0.0412 
(0.0120) 
0.0188 
Firmicutes____Anaerobacillus 0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0133 
(0.0001) 
0.0132 
(0.0000) 
0.0085 
Firmicutes____Lactobacillus 0.0056 
(0.0025) 
0.0008 
(0.0004) 
0.0107 
(0.0028) 
0.0132 
(0.0075) 
0.0071 
Firmicutes____Turicibacter 0.0018 
(0.0012) 
0.0003 
(0.0000) 
0.2021 
(0.0378) 
0.0775 
(0.0159) 
<0.0001 
Firmicutes____Clostridium 0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0133 
(0.0001) 
0.0133 
(0.0001) 
0.0108 
Firmicutes____SMB53 0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0204 
Firmicutes____Blautia 0.0132 
(0.0000) 
0.0136 
(0.0001) 
0.0132 
(0.0000) 
0.0142 
(0.0004) 
0.0008 
Firmicutes____Coprococcus 0.0205 
(0.0052) 
0.0160 
(0.0016) 
0.0091 
(0.0019) 
0.0234 
(0.0066) 
0.0424 
Firmicutes____Dorea 0.0008 
(0.0002) 
0.0015 
(0.0003) 
0.0013 
(0.0006) 
0.0040 
(0.0007) 
<0.0001 
Firmicutes____.Ruminococcus. 0.0100 
(0.0024) 
0.0100 
(0.0017) 
0.0050 
(0.0009) 
0.0098 
(0.0016) 
0.0183 
 
  
65 
 
Table 3. 3. (Continued).  
Bacteria Category CD CD+GTE MCD MCD+GTE 
Overall 
Model 
p-Value 
Firmicutes____Ruminococcus 0.0287 
(0.0085) 
0.0406 
(0.0040) 
0.0289 
(0.0058) 
0.0194 
(0.0037) 
0.0336 
Proteobacteria____Bilophila 0.0310 
(0.0070) 
0.0155 
(0.0023) 
0.0147 
(0.0006) 
0.0132 
(0.0000) 
0.01 
Proteobacteria____Desulfovibrio 0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0003 
Proteobacteria____Klebsiella 0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0132 
(0.0000) 
0.0096 
Verrucomicrobia___Akkermansia 0.0289 
(0.0172) 
0.1706 
(0.0339) 
0.1781 
(0.0362) 
0.1835 
(0.0385) 
<0.0001 
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Table 3. 3. MCD-induced liver injury alters the cecum bacterial profile. At the 
conclusion of the study, cecum samples were sent to Argonne National 
Laboratory where DNA extraction and 16S sequencing was performed and 
analyzed by the Quantitative Insights into Microbial Ecology (QIIME) program. 
Next, production of the PCR amplicon library, amplicon quantification and 
sequencing, and operation taxonomic units (OTUs) selection and filtration was 
conducted. For each type of bacteria, relative abundance means and standard 
errors were calculated for each group. p-value of <0.05 was considered 
significant. J.B. analyzed data and made figure with assistance from G.H. J.B.H. 
assisted with data analysis.  
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Figure 3.1. Experimental Design. 
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Figure 3.1. Experimental Design. Outline of the experimental groups, diet 
regimen, and study timeline. J.B. designed the study and timeline with 
consultation.  
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Figure 3.2.  MCD feeding increases hepatic steatosis and inflammation. 
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Figure 3.2.  MCD feeding increases hepatic steatosis and inflammation. (A) 
H&E staining of liver sections. Each image is illustrative per treatment group. A 
liver pathologist determined the percentage of macro vesicular fat in H&E stained 
hepatic sections. Mice livers were weighed post euthanasia. (B) Hepatic mRNA 
expression of inflammatory genes Tnf-α, Ccl2, and Pai-1 were measured. The 
plasma levels of ALT and AST were measured using the Piccolo Xpress 
Chemistry Analyzer. Values are mean ± SEM and different letters denote 
significant differences (p-value <0.05). J.B. performed data analysis and made 
figures. E.L. determined macrovesicular fat content.  
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Figure 3.3. MCD-induced liver injury alters the green tea metabolite profile. 
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Figure 3.3. MCD-induced liver injury alters the green tea metabolite profile. 
At week 8, mice from each group were randomly selected (n=3) and placed into 
solo mice urine collection cages for 24 hours. (A) The metabolite profile of four 
flavan-3-ols, epigallocatechin gallate (EGCG), epicatechin gallate (ECG), 
epigallocatechin (EGC), and epicatechin (EC) assessed by UPLC-Q MS. (B) The 
percentage of phase 2 conjugation metabolites in the urine was determined. J.B 
and P.D contributed equally to sample collection. P.D. analyzed data and made 
figure. 
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Figure 3.4. Liver injury modifies expression of hepatic, not intestinal, phase 
2 metabolizing enzymes. 
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Figure 3.4. Liver injury modifies expression of hepatic, not intestinal, phase 
2 metabolizing enzymes. The mRNA expression of intestinal and hepatic phase 
II metabolizing enzymes and transporters were measured using q-PCR. Values 
are mean ± SEM and different letters denote significant differences (p-value 
<0.05). J.B. conducted data analysis and made figures. 
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Figure 3.5. MCD-induced liver injury alters the bacterial phyla profile and 
the FB ratio. 
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Figure 3.5. MCD-induced liver injury alters the bacterial phyla profile and 
the FB ratio. At the conclusion of the study, cecum samples were sent to 
Argonne National Laboratory for DNA extraction and 16S sequencing. Data was 
analyzed using QIIME. (A) Taxonomic composition of the cecal microbiota at the 
phylum level at sacrifice. (B) Alpha diversity was determined by Shannon Index. 
Data presented as percent relative abundances. Values are mean ± SEM and 
different letters denote significant differences (p-value <0.05). J.B. conducted 
data analysis and made figures. J.B.H. assisted with data analysis.  
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Figure 3.6. Liver injury causes gut dysbiosis via alterations in the cecal 
bacterial profile. 
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Figure 3.6. Liver injury causes gut dysbiosis via alterations in the cecal 
bacterial profile. The relative abundance of the phyla Tenericutes, 
Verrucomicrobia and Bacteroidetes and the corresponding order RF39, and 
genera Akkermansia and Parabacteroides respectively. Data presented as 
percent relative abundances. Values are mean ± SEM and different letters 
denote significant differences (p-value <0.05). J.B. conducted data analysis and 
made figures. J.B.H. assisted with data analysis. 
 
  
  
79 
 
Chapter 4 Specific Aim 3: Test the hypothesis that the prebiotic fiber 
inulin can attenuate steatohepatitis and PCB-126 toxicity in wild type 
C57BL/6 mice 
 
Summary 
Scope: Exposure to environmental pollutants, namely PCBs, have been linked to 
a variety of inflammatory diseases including CVD and NAFLD. Research has 
begun to elucidate the interplay between fatty liver disease and pollutant toxicity, 
although studies observing the effects in severe liver injury models are lacking. 
Additionally, the liver’s intricate blood supply makes it susceptible to organ-organ 
system interactions, for example with the gut-microbiota. Previous studies in our 
lab showed that in the presence of a compromised liver, PCB toxicity and nutrient 
metabolism is altered, and the gut microbiota may play a major role in these 
results. Hence, this study sought to determine if prebiotic supplementation 
(inulin) can mitigate the effects of PCB-126 toxicity in a severe liver injury mouse 
model. 
 
Methods and Results: In this 8 week study, C57BL/6 mice were fed a purified 
MCD diet with the fiber source either as 8% cellulose or 8% inulin (wt/wt). At 
week 4 of the study mice were gavaged with either vehicle corn oil or PCB-126 
(0.5 mg/kg). Body weight was measured weekly. To assess body composition, 
EchoMRI was performed one week post PCB gavage (week 5) and at week 6 of 
the study, a GTT was performed to assess for glucose sensitivity. Post 
euthanasia blood and tissues samples were harvested for histological 
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examination and gene expression via q-PCR. H&E staining revealed that MCD-
diet fed mice exhibited steatosis although there was no observable effects of 
PCB-126 or inulin on macrovesicular fat content. Interestingly, both inulin 
supplemented groups displayed a restoration in body weight loss when 
compared to their MCD-diet only fed counterparts. Additionally, the MCD+Inulin 
group had an increase in the body fat mass and decrease in the body lean mass 
when compared to all other groups, suggesting a restoration of the lean, wasting 
phenotype seen with MCD-diet. With regards to glucose metabolism, there were 
no relevant effects of PCB-126 or inulin in this study. Interestingly in both PCB-
exposed groups, the AhR target Cyp1a1 was increased with inulin 
supplementation significantly decreasing Cyp1a1 expression.   
 
Conclusions: Considering all of the findings in this study, inulin was able to 
restore body weight and body composition in this PCB exposed severe injury 
mouse model. Interestingly the observed inulin effects may be a result of 
interactions with the AhR signaling pathway. However, since these findings are 
preliminary, further analysis is warranted. 
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Introduction 
Exposure to environmental pollutants have been implicated in the 
pathophysiology of many diseases. A specific class of persistent organic 
pollutants, PCBs, have been linked to the development of multiple chronic 
inflammatory diseases including atherosclerosis and NAFLD [32, 35]. Human 
exposure to PCBs are typically through consumption of contaminated food 
sources and there are a variety of mechanisms that has been proposed of how 
pollutant exposure can cause deleterious health outcomes and disease risk. 
Specifically, dioxin-like pollutants like PCB-126 can influence disease states by 
increasing inflammation and oxidative stress [89].  
Previously, we showed that in mice with pre-existing liver injury, PCB-126 
toxicity is worsened and exacerbates hepatic steatosis and inflammation as well 
as increased systemic inflammation [18]. In this same liver injury model, we also 
showed that nutrient metabolism was altered, possibly hindering the protective 
effects of GTE. An interesting finding in both these studies was that the gut 
microbiota may have contributed to these findings, as seen in Chapter 2 gut 
metabolites being excreted in liver injury mice simultaneously exposed to PCBs 
and the occurrence of gut dysbiosis in the MCD+GTE study of Chapter 3.  
One way to combat the effects seen in this dissertation is by increasing 
consumption of foods that are rich in beneficial nutrients such as polyphenols 
and prebiotics. Since we observed changes in the liver and the gut microbiota in 
both chapters, we desired to utilize an intervention that could target both organs, 
hence the prebiotic inulin was chosen for this study. Prebiotics are any 
  
82 
 
“selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity in the gastrointestinal microflora, that confers 
benefits” and play an important role in maintaining and influencing gut health 
[67]. In the food industry, inulin is a popular source for fiber supplementation and 
is one of the most ingested fiber components in the country, making it a practical 
means for intervention [117]. Also, recent research has shown that inulin has a 
major impact on multiple NAFLD-associated events such as body weight, body 
mass index, and serum levels of inflammatory and liver injury markers [71, 118]. 
Thus, inulin is a primary candidate for nutritional intervention in this mouse 
model.  
Taken altogether, the primary objective of this present study was to 
determine the ability of the prebiotic inulin to protect against the development of 
steatohepatitis and block PCB-126 toxicity. 
 
Experimental design and methods 
 
Animals, diet, and experimental design 
All aspects of this study were approved by the Institutional Animal Care 
and Use Committee at the University of Kentucky. Animals were housed in a light 
and temperature controlled room on a 12 hour light/dark cycle with food and 
water administered ad libitum. Eight week-old male C57BL/6 mice were 
purchased from Taconic (Hudson, NY, USA) and divided evenly into four 
experimental groups (n=10) during this 8-week study. During week 1 of the study, 
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mice were fed their respective control diets and at week 2, mice were fed a 
purified MCD diet with 8% cellulose as the source of fiber (MCD; TD.180883; 
Envigo) or a MCD diet with supplementation of the prebiotic inulin (Inulin; 
TD.180884; Envigo) at 8% (w/w) as the fiber source. Appropriate groups were 
orally gavaged with vehicle corn oil or PCB-126 (0.5 mg/kg) at week 4 of the 
study. To avert excessive weight loss and subsequent non-compliance with the 
approved IACUC protocol, all MCD mice were returned back to their respective 
control diets for one week (week 5) of this study.  
 
Inulin supplementation and dosage information  
Inulin was acquired from Beneo (Orafti® HP, Beneo). Inulin was 
supplemented into the MCD diet (TD.180883; Envigo) diet at 8% (w/w). The 
dosage of fiber selected for this study was chosen to mimic “high” fiber intake 
based on human dietary recommendations [65]. The customary level of fiber in 
purified rodent diets is 5% which equates to 12 grams per 1000 calories. The 8% 
of fiber used in this study can be considered as a “high” fiber diet as this equates 
to 21 grams per 1000 calories.  
 
Hepatic histological sectioning and examination  
At the completion of the study, liver tissues were immediately fixed in 10% 
neutral buffered formalin for 24-48 hours. The tissues were then sliced and 
hepatic sections were stained with hematoxylin and eosin (H&E) followed by 
examination by light microscopy. A liver pathologist assessed the stained 
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sections for macrovesicular fat percentage and inflammation. Reagents were 
obtained from Sigma-Aldrich Corp (St. Louis, MO, USA). Images were captured 
using a high resolution digital scanner at 10x magnification.  
 
Measurement of body composition 
Animals were analyzed via nuclear magnetic resonance spectroscopy 
(EchoMRI) for lean and body fat mass one week post PCB gavage (week 5) of 
the present study. In short, based on body weight, conscious mice were placed 
into breathable cylindrical plastic tubes. The mice inside the tubes were 
subsequently placed into a system that applies an external magnetic field and 
scanned for body composition.  
 
Glucose Tolerance Testing 
A glucose tolerance test (GTT) was conducted one week post PCB 
gavage (week 6) of the study. Mice were fasted during the light phase for 4-6 
hours and glucose was administered via intraperitoneal injection (i.p.) at 1 mg 
glucose/grams body weight in sterile saline. Fasting blood glucose levels were 
determined via a hand-held glucometer (Freestyle Freedom Lite Abbott, 
Alameda, CA, USA) utilizing 1-2 µL of blood via the tail vein. Subsequent blood 
glucose levels were measured at 15, 30, 60, and 120 minutes post injection.  
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RNA extraction and q-PCR 
Mouse liver and intestinal samples were homogenized using a bench top 
bead beater and total RNA was extracted using the TRIzol reagent (Invitrogen, 
Carlsbad, CA). The purity and concentrations of the mRNA was determined with 
the NanoDrop 2000/2000c (Thermo Fisher Scientific Inc., Waltham, MA, USA) 
using the NanoDrop 2000 software. Next, total RNA was used to synthesize 
complementary DNA using the QuantiTect Reverse Transcription Kit (Qiagen, 
Valencia, CA, USA) following manufacturer’s protocols. Polymerase chain 
reaction (PCR) was performed on the CFX96 Touch Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA, USA) using the Taqman Fast Advanced Master 
Mix (Thermo Fisher Scientific Inc.) to determine the expression of inflammatory 
and fibrotic markers. The mRNA levels for the liver were normalized to amount of 
Actb. Expression levels in the mice fed the MCD diet alone and administered 
vehicle were set at 1. The 2−ΔΔCt method was utilized to calculate the differences 
in gene expression levels [88]. All primers used in this study were obtained from 
Taqman Gene Expression Assays (Thermo Fisher Scientific Inc.).  
 
Statistical Analysis 
Analyses for all data represented in this study were conducted and 
corresponding graphs were plotted using GraphPad Prism Version 7.02 for 
Windows (GraphPad Software, Inc., La Jolla, CA). Data are expressed as mean 
mean ± SEM. Multiple group data was compared using Two Way ANOVA 
(column factor: diet row factor: Inulin) followed by the Tukey’s post-hoc test for 
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multiple comparisons. The results were considered to be statistically significant 
and with an observed p-value of < 0.05.  
Results 
4.1 Experimental Design 
 
The experimental design for this study is presented in Figure 4.1. 
 
4.2 MCD feeding induced steatosis with no PCB-126 or inulin effects  
 
 To examine steatosis in these mice, liver sections were stained with H&E. 
As expected, MCD-feeding caused an increase in the fat accumulation in the 
hepatocytes of all groups as seen by macrovesicular fat content. As determined 
by a liver pathologist, there were no observable PCB-126 or inulin effects in the 
mice with regards to steatosis (Figure 4.2). In addition, the LW/BW ratio was 
determined. We observed an increase in the LW/BW ratio in mice exposed to 
PCB-126, signifying toxicity. However inulin exerted no effects with regards to 
this parameter.  
 
4.3 Inulin restored body weight, fat, and lean mass in MCD-diet fed mice  
 
 MCD-feeding produces a lean phenotype in which mice experiences a 
decrease in body weight over time. Interestingly, when compared to the MCD-
diet only fed group, both groups with inulin supplementation exhibited a 
restoration of body weight loss as shown by a significant increase in the % 
increase body weight at the conclusion of the study (Figure 4.3). In addition to 
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the effects that were seen with body weight, the body composition was also 
measured via EchoMRI one week post PCB-126 gavage (Week 5). The 
MCD+Inulin group showed a significant increase in the body fat mass and a 
significant decrease in the body lean mass when compared to all other groups, 
suggesting a reversal of the lean, wasting phenotype caused by MCD-feeding 
(Figure 4.3).  
 
4.4 PCB-126 and Inulin do not exert physiological effects on glucose sensitivity  
 
 When compared to other models of liver disease and injury, an atypical 
characteristic of the MCD-fed rodent model is that the mice displays a 
hypoglycemic phenotype. To determine the effects that PCB-126 and inulin has 
on this phenomenon, a glucose tolerance test was conducted at week 6 of this 
study. There was no significant differences between any of the groups with 
regards to the fasting blood glucose (Figure 4.4). Furthermore, we observed no 
PCB-126 effect with area under the curve (AUC), although there was an inulin 
effect (p=0.0143). Taken altogether, we can infer that there was no major 
physiologically relevant effects with PCB-126 or inulin on blood glucose in this 
study.    
4.5 Inulin decreases AhR target gene Cyp1a1 mRNA levels with no effects on 
hepatic inflammation. 
 
 To further examine the effects that PCB-126 and/or inulin have on hepatic 
injury, we measured the gene expression of inflammatory and fibrotic markers. 
The MCD+PCB+Inulin group had an increase in the inflammatory Tnf-α when 
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compared to the MCD+Inulin alone group. Inulin also increased expression of 
Ccl2 when compared to the MCD alone group and the MCD+PCB group. 
Interestingly, both Timp-1 and Pai-1 were increased only in the MCD+PCB+Inulin 
group.  
To examine if AhR activation was involved in our findings in this study, the 
gene expression of its downstream target Cyp1a1 was determined. As expected 
both PCB exposed groups exhibited a significant increase in Cyp1a1 expression. 
Interestingly, inulin supplementation in the PCB exposed groups caused a 
significant decrease in Cyp1a1 expression.  
 
Discussion 
 
PCB-126 exposure has been linked to multiple chronic inflammatory 
diseases, including NAFLD. Data obtained from the studies presented in 
chapters 1 and 2 showed that a compromised liver can alter PCB-126 toxicity 
and GTE metabolism, with implications that the gut-microbiota may play a role in 
both of these outcomes [18]. Since the liver and the gut were prominent players 
in our results, we decided to study a nutritional intervention that could impact 
both organs, in addition to combatting the effects of PCBs. 
Inulin was chosen for use in this study for multiple reasons. Firstly, insulin 
has recently become a popular fiber supplementation source in the food industry, 
making it the one of the most ingested fibers in the U.S. with the average 
American consuming 1-4 grams of inulin-type fructans daily [117].This makes it a 
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readily accessible and feasible means of nutritional intervention. Secondly, 
emerging research suggests that inulin has beneficial host health effects. With 
regards to the research contained within this chapter, inulin has been shown to 
possess protective properties against the anthropometric, inflammatory, and 
oxidative parameters seen in patients with NAFLD such as decreasing body 
weight and body mass index in addition to decreasing serum levels of Tnf-α [71]. 
In another study, grades of NAFLD and serum levels of ALT and AST were all 
decreased in NAFLD patients administered a symbiotic yogurt containing inulin 
[118]. Studies in rodent of models of NAFLD also showed similar results when 
fed a natural dietary supplement containing inulin [72]. Interestingly, in other 
mouse models of NAFLD, inulin supplementation ameliorated hepatic steatosis 
[119, 120]. Therefore, inulin was selected for use in this study.  
First, we sought to examine the effects that PCB-126 and inulin could 
exert in mice with compromised liver. As determined by a liver pathologist, there 
were no significant differences between any of the groups with regard to 
macrovesicular fat content (H&E staining). However, we did observe an increase 
in the LW/BW ratio, a marker of toxicity, in both groups exposed to PCB-126 
although there was no inulin effect. This finding suggests that in mice with severe 
liver injury, toxicity is increased when exposed to PCB-126, which is consistent 
with our findings in chapter 2. Yet, inulin exerts no protective effects on steatosis 
in this study.  
 EchoMRI was performed one week post PCB gavage to further examine 
the effects of PCB-126 and inulin in this model. The MCD model is notorious for 
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producing a lean phenotype within mice, with animals exhibiting extreme weight 
loss while fed the diet [46]. As stated before, using mice with a lean phenotype 
that do not get obese is important for studies with lipophilic PCBs. As expected, 
mice fed the MCD diet displayed body weight loss over the course of the study 
as shown by the % increase in body weight over time. Interestingly, the 
MCD+Inulin group showed a restoration of body weight, body fat mass, and lean 
mass when compared to all other groups. Since most animal models of NAFLD 
typically are obese, to our knowledge this is the first report of inulin restoring 
body weight loss in animals with severe liver injury. 
 Since glucose metabolism plays an important role in the progression of 
NAFLD, we next conducted a GTT. There was no significant differences with any 
of the groups with regards to fasting blood glucose in this study. PCB-126 did not 
alter glucose levels, which was a similar finding to previous studies in our lab. 
Unfortunately, inulin did not exert any protective effects on glucose levels.  
The gene expression of markers of inflammation and fibrosis were also 
examined. We observed an increase in Tnf-α in the MCD+PCB+Inulin group 
when compared to MCD+Inulin alone. In addition, inulin increased the gene 
expression of Ccl2 when compared to the MCD alone group and the MCD+PCB 
group. When compared to mice fed the MCD alone, PCB-126 exposure did not 
increase the expression of Tnf-α, Ccl2, Timp-1, or Pai-1 in this study, which is 
contrary to our findings in chapter 2. It may be that the PCB-126 exacerbated 
effects were not yet pronounced with regards to these specific genes since the 
study presented in this chapter was conducted over 8 weeks while the study in 
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chapter 2 was a 14-week study. An interesting finding was that both Timp-1 and 
Pai-1 were increased only in the MCD+PCB+Inulin group when compared to all 
other groups. Timp-1 is a tissue inhibitor of metalloproteinases that is 
upregulated by inflammatory cytokines in NAFLD while Pai-1 is a major regulator 
of fibrosis and has been implicated in obesity-induced NAFLD pathogenesis 
[121, 122]. Although not many studies have examined the role of Timp-1 or Pai-1 
in end stage liver injury, studies have shown that pharmacological inhibition of 
Pai-1 can reduce hepatic steatosis in MCD-diet fed mice but had not effect on 
inflammation or fibrosis [123]. This finding was contrary to our hypothesis that 
inulin is protective in NAFLD. However, since there were only four genes 
associated with inflammation and fibrosis tested in this study currently, it is 
premature to draw that conclusion. Thus, future analysis will be conducted to 
confirm the results.  
To examine if activation of the AhR contributed to our findings in this 
study, q-PCR was conducted to measure the gene expression of the downstream 
AhR target Cyp1a1. As expected, both groups exposed to PCB-126 had a 
significant increase in Cyp1a1 gene expression. Interestingly, inulin 
supplementation decreased Cyp1a1 expression when compared to the 
MCD+PCB group alone although both groups were administered the same 
amount of PCB-126 (0.5 mg/kg). No other studies have reported an inulin 
specific decrease in Cyp1a1. One study showed that in high-fat and high 
sucrose-diet fed NAFLD rats, Cyp1a1 was decreased and inulin alleviated this 
reduction, however these rodents were not exposed to the AhR activating PCB-
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126 [120]. Nonetheless, we and others have observed that inulin can alter the 
expression of Cyp1a1, suggesting that inulin’s effects may be a result of its ability 
to interact with the AhR pathway. However, further studies would need to be 
conducted to tease out this mechanism.   
Taken altogether, the findings in this study shows that inulin can restore 
body weight and body composition in this MCD mouse model. In addition, the 
effects seen with inulin may be associated with alterations in the AhR signaling 
pathway. However, these findings are preliminary and further analysis would 
need to be conducted to confirm these results.  
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Figure 4.1 Experimental design. 
 
  
  
94 
 
Figure 4.1 Experimental design. Mice were divided into 4 study groups (n=10) 
based on Inulin supplementation and PCB126 exposure. The timeline for diet 
separation and PCB exposure regimen are also outlined in the figure. J.B. 
designed the study and timeline with consultation.  
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Figure 4.2 MCD feeding induced steatosis with no PCB-126 or inulin 
effects. 
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Figure 4.2 MCD feeding induced steatosis with no PCB-126 or inulin 
effects. Post euthanasia hepatic sections were stained with H&E. 
Macrovesicular fat content was determined by a liver pathologist. Each image is 
illustrative per treatment group. Mice livers were weighed post euthanasia and 
the liver to body weight ratio was calculated. Values are mean ± SEM and 
different letters denote significant differences (p-value <0.05). J.B. conducted 
data analysis and made figures. E.L. determined macrovesicular fat content. 
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4.3 Inulin restored body weight, fat, and lean mass in MCD-diet fed mice. 
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4.3 Inulin restored body weight, fat, and lean mass in MCD-diet fed mice. 
The % increase in BW was calculated and the BW at week 1 was taken as 
100%. Body mass composition was determined by EchoMRI at week 5 of the 
study. Values are mean ± SEM and different letters denote significant differences 
(p-value <0.05). J.B. conducted data analysis and made figures.  
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4.4 PCB-126 and Inulin do not exert physiological effects on glucose 
sensitivity. 
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4.4 PCB-126 and Inulin do not exert physiological effects on glucose 
sensitivity. A glucose tolerance test was performed at week 5 of the study. Mice 
were fasted for 4-6 hours and fasting blood glucose levels (mg/dL) were 
measured prior to the testing with a handheld glucometer (Freestyle Freedom 
Lite Abbott, Alameda, CA, USA) using 1-2 µL of blood via the tail vein. Glucose 
was given via intraperitoneal injection (i.p.) at 1 mg glucose/grams body weight in 
sterile saline and blood glucose levels were measured at 15, 30, 60, and 120 
minutes post injection. Values are mean ± SEM and different letters denote 
significant differences (p-value <0.05). J.B. conducted data analysis and made 
figures. 
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4.5 Inulin decreases AhR target gene Cyp1a1 with no effects on hepatic 
inflammation. 
 
  
  
102 
 
4.5 Inulin decreases AhR target gene Cyp1a1 with no effects on hepatic 
inflammation. The mRNA expression of AhR target gene Cyp1a1 and 
inflammatory and fibrotic genes Tnf-α, Ccl2, Timp-1, and Pai-1 were determined 
via q-PCR. The mRNA levels for the liver were normalized to amount of Actb. 
Expression levels in the mice fed the MCD diet alone and administered vehicle 
were set at 1. Values are mean ± SEM and different letters denote significant 
differences (p-value <0.05). J.B. conducted data analysis and made figures. 
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Chapter 5: Overall Discussion 
 
Summary 
 
 The general public’s exposure to pollutants like PCB-126 is still a 
significant health concern with detectable levels of these contaminants currently 
seen in human populations long after the banishment of these chemicals for 
industrial use [124, 125]. Unfortunately, every organ system in the human body 
can be impacted by pollutant exposure. PCBs also have been linked to multiple 
disease pathologies although the mechanisms of actions both at the cellular level 
and systemically are in general still unclear or inconclusive, proving that studies 
are still needed to be conducted to increase our knowledge and gain better 
understanding. There are variety of epidemiological studies linking pollutant 
exposure to NAFLD. For example, Cave et al. demonstrated an association 
between PCBs and increased levels of the plasma liver injury marker ALT, 
suggesting a correlation between pollutant exposure and NAFLD [35]. 
Additionally, with current therapeutic strategies to attenuate and even abolish 
NAFLD mainly focused on dietary and lifestyle interventions, it is important to 
understand how a compromised liver can alter the intentional beneficial effects of 
diet-derived nutrients.  
 The primary objective of the research contained in this dissertation was to 
determine how toxicity of PCBs is changed in individuals with severe liver injury 
and how beneficial nutrition can attenuate these effects. In chapter 2, we 
demonstrated that indeed PCB-126 toxicity is worsened in the presence of a 
compromised liver, with implications of the gut microbiota and its derived 
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metabolites (e.g. TMAO) in CVD risk. In chapter 3, we sought to understand if 
GTE could attenuate steatohepatitis null PCB-126 and we saw that surprisingly, 
GTE at the dose used in this study was not protective against severe liver injury 
in MCD-fed mice. However, it was also determined that in the presence of a 
compromised liver, mice have gut dysbiosis and simultaneously GTE metabolism 
is altered. This suggests that a compromised gut-liver axis can influence GTE 
metabolism in a negative way and possibly decrease the therapeutic effects of 
bioactive nutrients. With all this in mind, the study in chapter 3 sought to 
determine if a nutrient that has the ability to act on both the liver and the gut 
microbiota, the prebiotic inulin, can attenuate the effects of steatohepatitis in this 
liver injury mouse model. While the findings of this study are preliminary, we 
have evidence to support the notion that in MCD-fed mice, inulin can restore 
body weight and body composition and its effects may involve interactions with 
the AhR pathway. However, further analysis is needed to determine the direct 
effects that inulin plays in hepatic, systemic, and gut microbiota toxicity.  
Aim 1: A compromised liver worsens PCB-126 toxicity: Implications for the 
role of the gut microbiota 
 
 There are a variety of epidemiological and animal studies that support the 
idea that dioxin-like pollutants, like PCB-126, are linked to the development 
and/or progression of chronic inflammatory disease [55, 126-129]. The 
mechanisms of actions that may contribute to these disease pathologies involve 
the chronic activation of the AhR by ligand binding of co-planar PCBs, causing 
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oxidative stress and increased inflammation in both the target organs and 
peripheral vasculature [130]. In particular, it has been shown that dioxin-like 
pollutants are associated with NAFLD in rodent and clinical models [35, 80]. 
Although all of the above is true, it is not completely clear what role a 
compromised liver plays on PCB-126 toxicity and associated disease risks. The 
research described in chapter two of this dissertation tried to answer this 
literature gap by examining the effects of severe liver injury on PCB-126 toxicity 
in mice. 
 The selection of the rodent model used in the studies presented in this 
dissertation was important. We decided to use the MCD-diet to induce liver injury 
and study PCB effects for two main reasons. Firstly, we desired to use a diet-
derived mouse model that closely mimicked end stage liver disease. Secondly, 
ensuring that the mice did not become obese was crucial to studies including 
PCBs, as it has been shown that individuals can be protected from PCB effects 
during a weight loss phase [55]. In chapter 2, we determined that MCD-diet fed 
mice exposed to PCB-126 had worsened steatosis as determined by H&E 
staining, increased levels of plasma liver injury markers, and increased gene 
expression of inflammatory and fibrotic markers in the liver. As expected, we saw 
increased expression of the AhR target Cyp1a2 in both groups exposed to PCB-
126. Additionally, since recent literature has implicated the metabolite TMAO in 
CVD risk, we examined the effects that PCB-126 may exert on the levels of this 
molecule in our compromised liver model. Interestingly, hepatic Fmo3 and both 
hepatic and plasma TMAO was increased solely in the MCD+PCB-126 group. 
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This is important as it not only implicates pre-existing liver injury in the increased 
risk of PCB-126 associated CVD, but also suggests that the gut microbiota plays 
an important role in PCB-associated inflammatory disease pathology since 
TMAO is derived from actions of the gut and the liver. Finally, we proved that 
MCD+PCB-126 mice had increased levels of early markers of endothelial cell 
dysfunction and inflammatory cytokines. Taken altogether, the findings presented 
in chapter 2 provided novel evidence that suggests a compromised liver can 
exacerbate hepatic and systemic PCB-126 toxicity, with implications that the gut 
microbiota plays a major role in chronic inflammatory disease, specifically CVD, 
risk. Therefore, focusing research on determining the effects of the gut-liver axis 
on pollutant toxicity is important, in addition to finding therapeutic methods to 
attenuate these effects such as nutritional intervention with beneficial nutrients. 
 
Aim 2: GTE does not protect against steatohepatitis: Implications of the 
gut-liver axis on nutrient metabolism 
 
 Based on our findings from chapter 2 we then decided to study how 
nutritional intervention could mitigate the effects we observed. Previous studies 
in our lab and others have shown that GTE and its major metabolite EGCG can 
protect against pollutant induced-inflammatory outcomes and diseases including 
inflammation in endothelial cells and NAFLD [64, 95]. The mechanisms of action 
typically associated with this attenuation is through the anti-oxidant and anti-
inflammatory properties of GTE and its components, which acts on the same 
pathways that pollutants like dioxin-like PCBs target. However, the extent that 
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which GTE can protect against severe NAFLD is not well understood with most 
studies utilizing less severe animal models. As stated previously, it is important to 
study rodent models that mimic end stage liver injury, as 25% of those diagnosed 
with NAFLD eventually progress and are diagnosed with the more severe 
disease state. Additionally, the concomitant effects of GTE supplementation and 
PCB-126 in this MCD model is uncertain, thus we decided to conduct a study 
without PCB-126. Therefore, in chapter 3, severe liver injury was induced in mice 
through MCD-diet feeding and GTE was supplemented into the diet at the 
achievable 1% wt/wt in diet (~4 cups of tea or ~200 mL/cup per day). GTE did 
not decrease steatosis as determined by the quantification of macrovesicular fat 
content nor did it decrease the MCD-induced hepatic inflammation and injury as 
seen by unchanged gene expression levels and ALT and AST plasma levels. To 
our surprise, based on the finding listed above it was determined that GTE does 
not protect against MCD-induced steatohepatitis in this mouse model. 
 We then desired to determine an explanation for these findings. There are 
studies that have investigated and proven that severe liver injury can alter the 
metabolism of endogenous and exogenous molecules and can subsequently 
change the efficacy and bioavailability of these components. Hence, a similar 
phenomenon may the reason we did not see protection in this model. Urine 
samples from the mice in this study were collected at week 8. Interestingly, we 
observed a significant change in the GTE metabolite profile in MCD diet fed 
mice. Specifically, an increase in glucuronidation and sulfated metabolites and a 
decrease in the methylation and gut-microbiota catalyzed metabolites were 
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observed. To further examine the mechanisms associated with these metabolism 
alterations the gene expression of intestinal and hepatic transporters and phase 
2 metabolizing enzymes, in addition to the cecum microbiota profile were 
investigated. There were no significant changes in the intestinal gene expression 
for Comt, Ugt1a1, Sultb1, or Abbc2. We also observed no changes in hepatic 
Comt or Ugt1a1. However, expression of hepatic Sult1a1 and Abcc2 was 
significantly increased when compared to all other groups and the hepatic Abcc1 
was increased in both MCD-diet fed groups. Remarkably, a complete alteration in 
the cecum gut microbiota profile was seen in MCD groups as seen by changes in 
the taxonomic composition at phyla, order, family, and genus levels, signifying 
gut dysbiosis. 
 Overall, the findings from chapter 3 displayed that GTE does not protect 
against MCD-diet induced liver injury. However, this lack of protection may be 
due to the fact that in the presence of a compromised liver, the GTE metabolite 
profile is altered, namely via changes in glucuronidation, sulfation, methylation, 
and gut-microbiota derived metabolites. Additionally, results produced from this 
model implicates the gut microbiota in disease risk, as gut dysbiosis was 
observed in this compromised liver mouse model, possibly contributing to the 
effects seen in GTE alterations.   
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Aim 3: Inulin restores body weight and composition with possible 
interactions with the AhR signaling pathway 
 
In chapters 2 and 3 we saw that in mice with a compromised liver, PCB 
toxicity and nutrient metabolism (GTE) was altered, with a possible role of the gut 
microbiota. Therefore, in the study contained in chapter 4, we investigated if the 
prebiotic inulin could attenuate the deleterious effects of PCB-126 toxicity in a 
severe liver injury mouse model. In this 8 week study, male C57Bl/6 were fed a 
purified MCD diet with the fiber source either 8% cellulose or 8% inulin (wt/wt). 
The 8% inulin used in this study can be considered a “high” fiber diet. 
Appropriate groups were administered PCB-126 at 0.5 mg/kg via oral gavage at 
week 4.  
Inulin did not protect against MCD-induced liver injury while PCB-126 in 
both groups caused toxicity as seen by a significant increase in the LW/BW ratio. 
Interestingly as seen EchoMRI conducted one week post PCB gavage, inulin 
restored body weight and body composition by increasing the % increase body 
and fat mass and decreasing lean mass. To our knowledge this is the first report 
of inulin restoring body weight loss in animals with severe liver injury. This finding 
may be a result of inulin’s effects on PCB metabolism, although further studies 
would need to be conducted to evaluate this possibility.   
Additionally, a GTT was conducted to assess glucose metabolism and 
sensitivity. No significant differences were seen with any of the groups for fasting 
blood glucose and PCB-126 did not alter glucose levels, a similar finding to a 
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previous study in our lab. With regards to inulin, we observed no protective 
effects on glucose homeostasis.   
We then sought to examine hepatic inflammation in these mice. Tnf-α was 
increased in the MCD+PCB+Inulin group when compared to the MCD+Inulin 
group. Inulin increased the expression of Ccl2 when compared to the MCD alone 
and the MCD+PCB group. Contrary to our previous findings, PCB-126 did not 
have any effect on Tnf-α, Ccl2, Timp-1, or Pai-1. We speculate that PCB-126 
effects were not yet pronounced with these specific genes because of a 
difference in the study timeline of the current study and our previously published 
work (8 weeks vs 14 weeks). In the MCD+PCB+Inulin group both fibrotic markers 
Timp-1 and Pai-1 were increased when compared to all the other groups. This 
suggests that inulin and PCB-126 increases fibrosis, which is contrary to our 
hypothesis.  
With regards to AhR activation, not surprisingly both PCB-126 treated 
groups exhibited an increase in Cyp1a1 gene expression. However, prebiotic 
inulin supplementation decreased the gene expression of Cyp1a1 when 
compared to the MCD+PCB group alone. To our knowledge this is unique to our 
study as no other studies have reported an inulin specific decrease in Cyp1a1. 
These findings suggests that inulin’s effects may be because of its ability to 
interact with the AhR pathway, although additional mechanistic studies would 
need to be done. Overall the findings from chapter 4 displayed that inulin 
restores body weight and composition in mice with pre-existing liver injury and 
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these effects may be associated with the AhR signaling pathway. However, 
further analysis is warranted as the findings in this study are preliminary.  
 
Limitations 
 
Although the data presented in this dissertation adds to the growing body 
of evidence implicating the gut-liver axis in toxicant, nutrient and overall 
metabolism and health, no study is without limitations.  
The use of MCD-diet as a way to induce and study fatty liver disease is 
definitely something to consider, both for its ability to mimic human liver disease 
and within the context of this work. Since all patients with liver disease have the 
possibility of progressing to the far right end of the spectrum and 25% actually 
being diagnosed with end stage live disease, it is important to use a model that 
has the ability to generate a similar phenotype, hence the utilization of the MCD 
mouse model in these studies. In addition, there is animal studies and 
epidemiological evidence that supports the notion that leaner individuals may be 
more susceptible to the effects of lipophilic contaminants like dioxin-like PCBs 
because of the increased body burden of the pollutant from the lack of 
sequestration into the adipose tissue. For example, Baker et al. reported that 
mice with large fat depots due to weight gain were protected against the harmful 
effects of dioxin-like chemicals, while during a weight loss phase the mice 
demonstrated PCB-induced inflammation and glucose intolerance [55].  
However, although it is a robust model and produces a phenotype similar 
to human NASH, the MCD diet has recently been criticized for its lack of 
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metabolic characteristics that are traditionally seen in patients with fatty liver 
disease such as obesity and hyperglycemia. Although this is true and should be 
considered when using this model to mimic human disease, interestingly, recent 
literature has shown that in mice choline deficiency can occur under 
pathophysiological conditions as high fat diets can lead to the formation of gut 
bacteria that convert dietary choline to methylamines. This consequently reduces 
the systemic plasma phosphatidylcholine levels, generating a phenotype similar 
to the NASH producing choline-deficient diets.[131] Regardless, the use of other 
diet-induced liver injury mouse models, like the high fat diet (HFD), may be useful 
to compare and contrast the findings obtained in this dissertation.  
Another minor limitation that occurs in all of the studies presented in this 
dissertation is that the MCD diet fed mice were reverted back to their respective 
control diets for one week. As stated in above, this measure was taken to avoid 
excessive weight loss in these animals and subsequent non-compliance with our 
approved IACUC protocol. Although this resulted in a slight attenuation in the 
body weight loss of MCD diet fed mice, this does not cause a total recovery from 
the steatohepatitis that was observed, as confirmed by histological analysis post 
euthanasia. In fact, the reversal of MCD-induced hepatic effects typically occurs 
from 2-3 weeks of feeding a control diet [132].  
Lastly, the use of solely male mice does not account for any sex 
differences that may contribute to the findings. In point of fact, data obtained from 
the National Health and Nutrition Examination Survey displayed that individuals 
with NAFLD were more likely to be male, suggesting a sex disparity in regards to 
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this particular disease [133]. Since both the severity of liver disease and the gut 
microbiota may differ between sexes, future studies would need to include 
female mice to examine the contribution that gender may have on the changes 
that were observed [134, 135]. 
 
Future Directions 
 
 There are variety of directions to take with future studies and the options 
are endless. Firstly, in chapter 2, since we observed increases in markers early 
endothelial cell dysfunction, it may be worthwhile to verify CVD risk and 
development in atherosclerotic animal models. Additionally, with the possible 
effects of the gut-microbiota seen in studies presented in chapters 2 and 3, 
teasing out the mechanisms that cause the gut-liver axis to exert its effects may 
be a next step, which would include the use of germ free mice or antibiotic 
treatment. Additionally, using other animal models of liver injury to compare our 
results would be of interest including a high fat or high-sucrose diet.  
The study presented in chapter 4 has a lot of potential. Analysis of the gut 
microbiota profile could help gain a better understanding of its role in PCB 
mediated toxicity and inulin protection. In addition, no systemic inflammatory 
markers were measured as of yet, so obtaining plasma ALT, AST, and cytokine 
data would help to determine if PCB-126 exacerbates inflammation and liver 
injury in this model or if inulin has any protective effects. In addition, since we 
observed alterations in the expression of genes downstream the AhR, studies 
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looking into whether inulin can impact other targets of the pathway or even 
interact with AhR itself.  
In conclusion, the data within this dissertation demonstrates that in the 
presence of a compromised liver both PCB-126 toxicity and GTE metabolism is 
altered, with implications of the gut-microbiota in disease risk. The results 
suggest that there is increased susceptibility to pollutant-induced toxicity for 
human populations with the end stage of liver disease. Additionally nutritional 
intervention with beneficial nutrients may be unsuccessful at attenuating disease.  
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